# SHORT TERM EVALUATION OF THE SOOTHING AND RE-EPITHELIZING ACTIVITY OF IDRO/LIPO-GEL FORMULATIONS VS REFERENCE PRODUCTS

PROTOCOLS N°: 2647, 2648, 2649, 2650

TEST CODE: E0715

**SUBMITTED TO: Fondazione Samiarc** 

Via Lanzone, 7

20123 MILANO (MI)

**ITALY** 

PRODUCTS:

**LIPOGEL SOLUZIONE P 1%** 

**IDROGEL SOLUZIONE B** 

LIPOGEL SOLUZIONE CONTROLLO 1%

**IDROGEL SOLUZIONE CONTROLLO** 



DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

#### INDEX

#### FINAL REPORT

- 1. SUMMARY OF THE PROTOCOL
- 1.1. STUDY OBJECTIVE AND DEFINITIONS
- 1.2. CHARACTERISTICS OF THE POPULATION AT INCLUSION
- 1.3. SUMMARY OF THE STUDY METHODOLOGY
- 2. RESULTS
- 2.1. SOOTHING EFFICACY
- 2.1.1. Erythema index (E.I. Optical densitometry)
- 2.1.2. Skin erythema (Optical colorimetry)
- 2.1.3. Clinical evaluation on skin erythema
- 2.2. RE-EPITHELIZING EFFICACY
- 2.2.1. Skin hydration
- 2.2.2. Epicutaneous pH
- 2.2.3. Transepidermal water loss (TEWL)
- 2.2.4. Microrelief surface evaluation (Profilometry)
- 3. CONCLUSIONS
- GRAPHS
- RAW DATA TABLES
- STATISTICAL ANALYSIS SUMMARY TABLES

#### **PROCEDURE**

- 1. AIM OF THE STUDY
- 2. MATERIALS
- 3. STUDY DESIGN
- 4. RECRUITMENT OF THE VOLUNTEERS
- 4.1. Recruitment, selection and admission
- 4.2. Characteristics of the population to be included
- 4.3. Source
- 4.4. Recruitment of the volunteers
- 4.4.1. Inclusion criteria
- 4.4.2. Exclusion criteria

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

4.4.2.1. Dependent on the volunteers' characteristics 4.4.2.2. Dependent on a clinical condition 4.4.2.3. Dependent on a pharmacological treatment 4.5. Restrictions

#### 5. CASE REPORT FORM

#### 6. SAMPLES ACCEPTANCE, IDENTIFICATION AND APPLICATION

- 6.1. Samples record
- 6.2. Samples storage
- 6.3. Site of application
- 6.4. Quantity of products applied
- 6.5. Application and absorption of the study products

#### 7. TREATMENT EVALUATION

- 7.1. Preliminary examination
- 7.2. Skin erythema induction
- 7.3. Soothing efficacy evaluation
- Clinical evaluation of skin erythema 7.3.1.
- 7.3.2. Instrumental evaluation of skin erythema
- 7.3.2.1 Optical densitometry
- 7.3.2.2. Optical colorimetry
- 7.4. Re-epitelizing efficacy evaluation
- 7.4.1. Transepidermal water loss (TEWL)
- 7.4.2. Electrical capacitance of skin (superficial hydration)
- 7.4.3. Tissue dielectric constant of deep skin layers (deep hydration)
- 7.4.4. Epicutaneous pH
- Microrelief surface evaluation (profilometry) 7.4.5.
- 7.5. Standard conditions for the treatment evaluations

#### SCHEDULE OF STUDY PROCEDURE 8.

- 8 1. Baseline visit (T0)
- Intermediate visits (1, 6, and 24 hours after products application) 8.2.
- 8.3. Final visit (48 hours after products application)

#### PREMATURE END OF THE STUDY/END OF THE STUDY 9.

9.1. Withdrawal criteria

> DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

- 9.2. Procedure
- 9.3. Restrictions
- 10. STATISTICAL ANALYSIS PLAN
- 10.1. Main criteria
- 10.2. Population description
- 10.3. Clinical data
- 10.4. Instrumental data
- 10.5. Statistical plan
- 11. QUALITY CONTROL AND ASSURANCE
- 12. ETHIC
- 12.1. Commitment attestation of insurance
- 12.2. Consent form for the volunteer
- 13. BIBLIOGRAPHY
- 14. APPENDICES

**APPENDICES** 

DermIng S.r.I., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

# FINAL REPORT

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

#### FINAL REPORT

# SHORT TERM EVALUATION OF THE SOOTHING AND RE-EPITHELIZING ACTIVITY OF IDRO/LIPO-GEL FORMULATIONS **VS REFERENCE PRODUCTS**

**TEST CODE: E0715** 

DATE: May 29th 2015

SUBMITTED TO: FONDAZIONE SAMIARC

Via Lanzone, 7

20123 MILANO (MI)

**ITALY** 

STUDY PRODUCT: LIPOGEL SOLUZIONE P 1%

PROTOCOL N°: 2647

**CONTAINER TYPE:** 

-MATERIAL: plastic

-FORM: dispenser

-COLOUR: transparent white

PRODUCT:

-QUANTITY: 30 ml

-PHYSICAL FORM: gel

-COLOUR: transparent

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

STUDY PRODUCT: LIPOGEL SOLUZIONE CONTROLLO 1%

PROTOCOL N°: 2648

CONTAINER TYPE: -MATERIAL: plastic

-FORM: dispenser

-COLOUR: transparent white

PRODUCT: -QUANTITY: 30 ml

-PHYSICAL FORM: gel -COLOUR: transparent

STUDY PRODUCT: IDROGEL SOLUZIONE CONTROLLO

PROTOCOL N°: 2649

CONTAINER TYPE: -MATERIAL: plastic

-FORM: dispenser

-COLOUR: transparent white

PRODUCT: -QUANTITY: 30 ml

-PHYSICAL FORM: gel

-COLOUR: transparent

STUDY PRODUCT: IDROGEL SOLUZIONE B

PROTOCOL N°: 2650

CONTAINER TYPE: -MATERIAL: plastic

-FORM: dispenser

-COLOUR: transparent white

PRODUCT: -QUANTITY: 30 ml

-PHYSICAL FORM: gel

-COLOUR: transparent

PRODUCTS ARRIVAL DATE: April 07th 2015

STUDY START DATE: April 27<sup>th</sup> 2015

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

RESPONSIBLES OF THE STUDY:

Dermatologist, Research Director: Dr. Adele Sparavigna

Signature:

Project manager: Dr. Beatrice Tenconi

Signature:

Quality assurance: Dr. Ileana De Ponti

Signature: R D RI;

STUDY CONDUCTED BY: DermIng S.r.I., Clinical Research and Bioengineering Institute, Viale Cesare Battisti, 38 – 20900 Monza (MB) - Italy

## 1. SUMMARY OF THE PROTOCOL

#### 1.1. STUDY OBJECTIVE AND DEFINITIONS

Open clinical study to evaluate the soothing and re-epithelizing activity of a single application of two gel formulations ("Lipogel soluzione P1%" and "Idrogel soluzione B") on experimentally induced erythema by repeated tape stripping on the forearm (volar surface) of 20 healthy volunteers.

Products study activity was assessed in comparison to two reference products ("Lipogel soluzione controllo 1%" and "Idrogel soluzione controllo").

## 1.2. CHARACTERISTICS OF THE POPULATION AT INCLUSION

The study was conducted on 21 healthy volunteers (18 females and 3 males), aged between 20 and 68 years (mean= 51), whose informed consent had been obtained.

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

#### 1.3. SUMMARY OF THE STUDY METHODOLOGY

To investigate the activity of the study products, a visible skin erythema was induced, for each volunteer, on 4 different adjacent skin areas of the forearms (volar surface - 2 areas on each side) by "repeated tape stripping" technique (see procedure par. 7.2), as follows:

- area treated with "Lipogel soluzione P1% (named during the test "P1")
- area treated with "Idrogel soluzione B" (named during the test "P2")
- area treated with "Lipogel soluzione controllo 1%" (named during the test "Ref1")
- area treated with Idrogel soluzione controllo" (named during the test "Ref2").

These areas were turned in accordance with a previously defined randomisation list (see "Subjects' randomisation list" table).

A fixed quantity of 1 ml (see procedure par. 6.4 and 6.5) of each product was prepared immediately before application, applied on the assigned skin area of 14 cm<sup>2</sup> (by a trained technician, by gloved fingers and light massage) and left absorbing on the skin for at least 15 minutes.

**Soothing efficacy** of the tested products was determined by clinical (visual score) and instrumental (optical densitometry and colorimetry) evaluations of skin erythema (see procedure par. 7.3), while **re-epythelizing activity** was defined by the measurement of:

- transepidermal water loss (TEWL see procedure par. 7.4.1)
- skin electrical capacitance (hydration see procedure par.7.4.2)
- tissue dielectric constant of deep skin layers (deep hydration see procedure par. 7.4.3)
- epicutaneous pH (see procedure par. 7.4.4)
- surface microrelief profilometry (see procedure par 7.4.5).

All evaluations were carried out at baseline (T0 - immediately after stripping execution) and 1 (T1h), 6 (T6h), 24 (T24h) and 48 (T48h) hours after study products application, except for the surface microrelief profilometry performed at T0 and T48h by image analysis (Primos compact portable device - GFMesstechnik).

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

#### 2. RESULTS

Obtained results are summarised below and detailed in the annexed graphs and tables.

Volunteer N. 17 was excluded from the study because the TEWL values measured at T0 were lower than the threshold values (≥15g/m²-h) required by the study procedure as index of a skin barrier damage induced by repeated tape stripping (see procedure par. 4.4.1).

The statistical analysis was performed on the data of 20 subjects who meet the inclusion criteria, in accordance to our internal procedures (descriptive and inferential analysis) as follows:

#### > Evaluation vs basal conditions (T0)

For each study area, comparison of the different study times (T1h, T6h, T24h and T48h) versus T0 using :

#### - for the clinical evaluations

Friedman test followed, in case of statistically significant result by Dunnett test.

## - for the instrumental evaluations (excluding profilometric parameters)

non-parametric test (Friedman test) when the normality hypothesis was rejected by the Shapiro-Wilk normality test (threshold at 5%) or parametric test (ANOVA for repeated-measures), when the normality hypothesis was confirmed and followed in case of statistically significant result by Dunnett/Tukey test.

#### - for the profilometric parameters

non-parametric test (Wilcoxon test) when the normality hypothesis was rejected by the Shapiro-Wilk normality test (threshold at 5%) or parametric test (Student t test) when the normality hypothesis was confirmed.

## Comparison among the 4 skin tested areas time by time

#### - for the clinical evaluations

Kruskal Wallis test followed, in case of statistically significant result by Tukey test.

#### - for the instrumental evaluations

non-parametric test (Kruskal Wallis test) when the normality hypothesis was rejected by the Shapiro-Wilk normality test (threshold at 5%) or parametric test (one way ANOVA

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

test), when the normality hypothesis was confirmed and followed in case of statistically significant results by Tukey test.

#### 2.1. SOOTHING EFFICACY

#### 2.1.1. Erythema index (E.I. – Optical densitometry)

Stripping corneum determined on all areas a significant increase of skin erythema index measured by optical densitometry; this alteration resulted similar for all tested areas (see raw data tables); in fact no clinical or statistical difference was found at T0 among the 4 compared areas.

The following table summarizes the obtained variation percentages vs T0:

OPTICAL DENSITOMETRY	Variation (%) vs T0			
	T1h	T6h	T24h	T48h
LIPOGEL SOLUZIONE P 1%	-26.1% (*)	-16.1% (*)	-27.8% (*)	-28.9% (*)
IDROGEL SOLUZIONE B	-21.7% (*)	-21.5% (*)	-28.3% (*)	-30% (*)
LIPOGEL SOLUZIONE CONTROLLO 1%	-22.5% (*)	-13.9% (*)	-27.8% (*)	-26% (*)
IDROGEL SOLUZIONE CONTROLLO	-25.9% (*)	-11.5% (*)	-25.3% (*)	-24.7% (*)

<sup>(\*)</sup> Dunnett test p<0.05 vs T0

Starting from T1h, a clinically or statistically (Dunnettt test p<0.05 vs T0) significant reduction of erythema index (E.I.) versus baseline (T0) was obtained on each treated area.

Although, at any study time, no statistically difference was highlighted between the 4 tested areas, the most clinically significant E.I. reduction was found starting from T6h for the skin area treated with *IDROGEL SOLUZIONE B*, and at T1h and T48h also for the skin area treated with *LIPOGEL SOLUZIONE P 1%*.

#### 2.1.2. Skin erythema (Optical colorimetry)

Skin colour is a mixture of the L\* (white-black), a\* (red-green) and b\* (blu-yellow) values. The statistical analysis performed on a\* parameter data (a\* positive values indicate skin redness) showed, already at T1h, a significant reduction of this parameter, index of a lowering of skin erythema achieved for all the skin areas under study (Dunnett test p<0.05 T1h, T6h, T24h and T48h vs T0).

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

The following table summarized the percentages of reduction vs T0:

OPTICAL COLORIMETRY a* parameter	Variation (%) vs T0			
	T1h	T6h	T24h	T48h
LIPOGEL SOLUZIONE P 1%	-27.9% (*)	-16.7% (*)	-25.8% (*)	-28.6% (*)
IDROGEL SOLUZIONE B	-22.7% (*)	-14.2% (*)	-24.8% (*)	-25.8% (*)
LIPOGEL SOLUZIONE CONTROLLO 1%	-23% (*)	-11.4% (*)	-21.5% (*)	-23.2% (*)
IDROGEL SOLUZIONE CONTROLLO	-24.1% (*)	-11.7% (*)	-23.6% (*)	-23.8% (*)

<sup>(\*)</sup> Dunnett test p<0.05 vs T0

No statistically differences was highlighted among the 4 tested areas, but the obtained results confirm a more marked anti-redness activity of *LIPOGEL SOLUZIONE P 1%* and of *IDROGEL SOLUZIONE B*, starting respectively from T1h and T6h.

No statistically or clinically significant variation of L\* (skin brightness) and b\* (skin pigmentation) parameters was detectable at any study time.

#### 2.1.3. Clinical evaluation of skin erythema

Skin stripping determined on all skin study areas a visible skin redness; already 1 hour after products application skin redness visual score was statistically reduced (Dunnett test p<0.05 T1h, T6h, T24h, T48h vs T0) on each tested area (see table below). No significant difference among the 4 tested products was showed at any study time, but on the skin areas treated with the IDROGEL SOLUZIONE B it is possible to note a more marked and clinically relevant decrease of skin basal erythema starting from T6h.

ERYTHEMA VISUAL SCORE		Variation (%) vs T0		
	T1h	T6h T24h T48h		
LIPOGEL SOLUZIONE P 1%	-35.8% (*)	-20.9%	-56.4% (*)	-77.7% (*)
IDROGEL SOLUZIONE B	-27.6% (*)	-41.4% (*)	-67.5% (*)	-82.2% (*)
LIPOGEL SOLUZIONE CONTROLLO 1%	-39.9% (*)	-29.4%	-61.4% (*)	-75.2% (*)
IDROGEL SOLUZIONE CONTROLLO	-41.8% (*)	-35.8%	-54.5% (*)	-74% (*)

(\*) Dunnett test p<0.05 vs T0

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

#### 2.2. RE-EPITHELIZING EFFICACY

#### 2.2.1. Skin hydration

Measurements of skin hydration were performed:

- on skin surface by Corneometer CM825 (see procedure par. 7.4.2)
- on deep skin layers (see procedure par. 7.4.3) by MoistureMeterD.

IDROGEL SOLUZIONE CONTROLLO and IDROGEL SOLUZIONE B determined at T1h a statistically significant increase (Tukey test p<0.05 T24h vs T0) of skin hydration mean value vs T0 respectively of 19% and 14.2%, index of an immediate moisturizing activity that gradually decreases within 48 hours.

Regarding LIPOGEL SOLUZIONE P 1% a statistically significant increase of skin hydration was detectable at T6h (+14.9%, Dunnett test p<0.05 T6h vs T0), while for LIPOGEL SOLUZIONE CONTROLLO 1% no statistically significant improvement of the considered parameter was found.

Moreover a single application of IDROGEL SOLUZIONE B determined already at T1h an important reduction of deep hydration (1.5 mm), index of an activity control of skin irritation/damage induced by tape stripping on the deep skin layers. A T48h the reduction percentage resulted statistically significant vs T0 (Dunnett test p<0.05 T48h vs T0).

On the contrary at T24h for IDROGEL SOLUZIONE CONTROLLO, a statistically significant increase of deep hydration was showed (Dunnett test p<0.05 T24h vs T0).

This trend is clinically comparable to the one obtained for the lipogel reference formulation (LIPOGEL SOLUZIONE CONTROLLO 1%).

#### 2.2.2. Epicutaneous pH

The application of IDROGEL SOLUZIONE B and IDROGEL SOLUZIONE CONTROLLO determined at T1h a statistically significant decrease of pH mean values, probably imputable to the presence of alcohol in both formulations. In fact already at T6h this effect tends to reduce and at T24h the variation percentages vs T0 are similar to the ones obtained for the 2 lipogel formulations.

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

#### 2.2.3. Transepidermal water loss (TEWL)

Stripping corneum determined on all skin study areas an increase of TEWL mean value; this alteration resulted similar for all tested areas (see raw data tables); in fact no clinical or statistical difference was found at T0 among the 4 compared formulations.

A single study products application determined, already at T1h, a clinically/statistically significant reduction of TEWL (Dunnett test p<0.05 T1h vs T0), index of an important "re-epithelizing" activity, in percentage more marked at T24h and at T48h for IDROGEL SOLUZIONE B.

### 2.2.4. Microrelief surface evaluation (Profilometry)

A picture of each skin area was taken at T0 and T48h thanks to Primos compact portable device (GFMesstechnik); the image analysis of surface roughness was performed using the "surface roughness evaluation" function. In particular, the profilometric parameter analyzed in this study was Sa (average roughness of the analyzed profile), that represents an overall measure of the surface texture.

The following table summarized the percentages of variation vs T0:

SKIN SURFACE PROFILOMETRY	Variation (%) T48h vs T0
	Sa
LIPOGEL SOLUZIONE P 1%	+5%
IDROGEL SOLUZIONE B	+7% (**)
LIPOGEL SOLUZIONE CONTROLLO 1%	+5.2%
IDROGEL SOLUZIONE CONTROLLO	+0.5%

Student t test (\*\*) p<0.01 vs T0

Although no statistically significant difference among the 4 tested area was showed at any study time, obtained results highlighted for the product IDROGEL SOLUZIONE B a clinically and statistically significant increase of Sa profilometric parameter, index of an important reepithelizing activity of the tested formulation, more marked than the one showed for the reference product (IDROGEL SOLUZIONE CONTROLLO) and for the two lipogels.

DermIng S.r.l., Clinical Research and Bioengineering Institute
Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY
Tel.: 039/329666 - www.derming.com

Test code
E0715


#### 3. CONCLUSIONS

Considering the soothing and re-epithelizing efficacy of the tested products, the best results were obtained for the formulation "IDROGEL SOLUZIONE B"; in fact a single application of this gel determined the most important efficacy on skin erythema and skin microrelief restoring, caused by stripping procedure.


DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

# **GRAPHS**


DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com




Statistical analysis: Dunnett test \*p<0.05 vs T0




Statistical analysis: Dunnett test \* p<0,05 vs T0




Statistical analysis: Dunnett test \*p<0.05 vs T0




Statistical analysis: Dunnett test \* p<0,05 vs T0



Statistical analysis: Dunnett test \*p<0.05 vs T0




Statistical analysis: Dunnett test \* p<0,05 vs T0




Statistical analysis: Tukey test \*p<0.05 vs T0


E0715




Statistical analysis: Tukey test \* p<0,05 vs T0




Statistical analysis: Tukey test \* p<0,05 vs T1h




Statistical analysis: Dunnett test \*p<0.05 vs T0




Statistical analysis: Dunnett test \* p<0,05 vs T0




Statistical analysis: Dunnett test \*p<0.05 vs T0



Statistical analysis: Dunnett test \* p<0,05 vs T0




Statistical analysis: Dunnett test \*p<0.05 vs T0



Statistical analysis: Dunnett test \* p<0,05 vs T0

E0715



Statistical analysis: Student t test \*\*p<0.01 vs T0

# RAW DATA TABLES

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

## **VOLUNTEERS' GENERAL TABLE**

VOL. N	INITIALS	SEX	AGE
1	EMN	F	53
2	CL	F	48
3	LA	F	64
4	FC	F	51
5	PL	F	29
6	DMR	F	66
7	LFC	M	45
8	SAM	F	53
9	BS	F	60
10	PP	F	55
11	VM	F	56
12	SE	F	62
13	PM	M	42
14	DM	F	46
15	TM	F	20
16	FB	F	52
17	DN	М	68
18	OF	F	52
19	DPI	F	31
20	MP	F	58
21	CD	F	58
MEAN			51
MIN			20
MAX			68

## SUBJECTS' RANDOMISATION LIST

VOL. N.	RIGHT FOREARM ELBOW	RIGHT FOREARM WRIST	LEFT FOREARM ELBOW	LEFT FOREARM WRIST
1	P2	P1	REF2	REF1
2	P1	REF1	P2	REF2
3	P1	P1	P2	REF2
4	REF2	P2	REF1	P1
5	P2	P1	REF2	REF1
6	P2	P1	REF2	REF1
7	P1	REF1	P2	REF2
8	REF1	REF2	P1	P2
9	REF2	P2	REF1	P1
10	P2	P1	REF1	REF2
11	P2	P1	REF2	REF1
12	P1	REF1	P2	REF2
13	REF1	REF2	P1	P2
14	REF2	P2	REF1	P1
15	P2	P1	REF2	REF1
16	P2	P1	REF2	REF1
17	P1	REF1	P2	REF2
18	P1	P2	REF2	REF1
19	REF2	P2	REF1	P1
20	P2	P1	REF2	REF1
21	P2	P1	REF2	REF1

LEGEND:

P1 = Lipogel soluzione P2 = Idrogel soluzione B P 1%

REF1 = Lipogel soluzione controllo 1%

REF2 = Idrogel soluzione controllo

#### **INSTRUMENTAL EVALUATION**

#### **OPTICAL DENSITOMETRY**

#### **ERYTHEMA INDEX**

## LIPOGEL SOLUZIONE P 1% (prot. 2647)

VOL N.	T0 - BASELINE (immediately after stripping)	T1h (1 hour after product application)	product application)	T24h (24 hours after product application)	product application)
1	0,17	0,15	0,16	0,14	0,12
2	0,17	0,09	0,08	0,09	0,08
3	0,18	0,11	0,11	0,09	0,11
4	0,17	0,11	0,13	0,12	0,14
5	0,16	0,09	0,11	0,13	0,13
6	0,24	0,20	0,24	0,21	0,19
7	0,18	0,18	0,23	0,18	0,17
8	0,23	0,14	0,23	0,19	0,17
9	0,22	0,15	0,14	0,13	0,11
10	0,16	0,13	0,17	0,09	0,14
11	0,17	0,11	0,13	0,11	0,10
12	0,14	0,10	0,12	0,08	0,09
13	0,22	0,20	0,19	0,18	0,18
14	0,17	0,15	0,13	0,11	0,12
15	0,13	0,07	0,15	0,12	0,10
16	0,16	0,12	0,13	0,13	0,13
17	[0,11]	NE	NE	NE	NE
18	0,21	0,17	0,21	0,19	0,17
19	0,12	0,09	0,09	0,06	0,07
20	0,18	0,13	0,15	0,13	0,11
21	0,22	0,16	0,12	0,12	0,13
MEAN	0,180	0,133	0,151	0,130	0,128
ST. DEV.	0,033	0,037	0,047	0,041	0,034
MIN	0,12	0,07	0,08	0,06	0,07
MAX	0,24	0,20	0,24	0,21	0,19
MSE	0,007	0,008	0,010	0,009	0,008

Legend: NE = not evaluated

VARIATION (%) vs T0					
T1h T6h T24h T48h					
-26,1%	-16,1%	-27,8%	-28,9%		

Statistical analysis: Dunnett test p<0,05 T1h, T6h, T24h and T48h vs T0

### **OPTICAL DENSITOMETRY**

### **ERYTHEMA INDEX**

### **IDROGEL SOLUZIONE B (prot. 2650)**

VOL N.	T0 - BASELINE (immediately after stripping)	T1h (1 hour after product application)	product application)	product application)	T48h (48 hours after product application)
1	0,21	0,15	0,14	0,16	0,14
2	0,16	0,15	0,08	0,13	0,11
3	0,15	0,12	0,11	0,10	0,12
4	0,10	0,07	0,10	0,10	0,12
5	0,18	0,09	0,09	0,09	0,12
6	0,28	0,19	0,22	0,19	0,20
7	0,24	0,21	0,21	0,18	0,18
8	0,18	0,20	0,21	0,16	0,16
9	0,20	0,16	0,15	0,11	0,08
10	0,16	0,14	0,12	0,11	0,11
11	0,19	0,13	0,13	0,11	0,10
12	0,11	0,10	0,13	0,08	0,09
13	0,21	0,21	0,20	0,17	0,19
14	0,17	0,16	0,14	0,14	0,12
15	0,14	0,14	0,16	0,14	0,12
16	0,20	0,12	0,12	0,14	0,12
17	[0,1]	NE	NE	NE	NE
18	0,19	0,16	0,19	0,21	0,17
19	0,13	0,07	0,08	0,06	0,07
20	0,18	0,09	0,09	0,08	0,08
21	0,22	0,15	0,16	0,12	0,12
MEAN	0,180	0,141	0,141	0,129	0,126
ST. DEV.	0,043	0,043	0,045	0,040	0,037
MIN	0,10	0,07	0,08	0,06	0,07
MAX	0,28	0,21	0,22	0,21	0,20
MSE	0,010	0,010	0,010	0,009	0,008

Legend: NE = not evaluated

	VARIATION	l (%) vs T0	
T1h	T6h	T24h	T48h
-21,7%	-21,5%	-28,3%	-30,0%

### **OPTICAL DENSITOMETRY**

### **ERYTHEMA INDEX**

### LIPOGEL SOLUZIONE CONTROLLO 1% (prot. 2648)

VOL N.	T0 - BASELINE (immediately after stripping)	T1h (1 hour after product application)	product application)	product application)	T48h (48 hours after product application)
1	0,17	0,16	0,19	0,16	0,18
2	0,12	0,10	0,08	0,07	0,07
3	0,15	0,10	0,11	0,09	0,11
4	0,17	0,11	0,15	0,13	0,15
5	0,15	0,09	0,12	0,15	0,15
6	0,23	0,19	0,21	0,16	0,19
7	0,19	0,18	0,23	0,19	0,18
8	0,22	0,16	0,18	0,16	0,10
9	0,20	0,17	0,14	0,13	0,10
10	0,18	0,16	0,17	0,15	0,17
11	0,18	0,13	0,17	0,14	0,10
12	0,12	0,10	0,07	0,07	0,10
13	0,19	0,14	0,14	0,14	0,12
14	0,16	0,16	0,11	0,10	0,14
15	0,13	0,08	0,15	0,10	0,09
16	0,17	0,14	0,14	0,13	0,14
17	[0,1]	NE	NE	NE	NE
18	0,21	0,16	0,22	0,10	0,17
19	0,15	0,10	0,12	0,07	0,07
20	0,15	0,07	0,11	0,12	0,11
21	0,21	0,17	0,17	0,13	0,12
MEAN	0,173	0,134	0,149	0,125	0,128
ST. DEV.	0,032	0,037	0,044	0,034	0,037
MIN	0,12	0,07	0,07	0,07	0,07
MAX	0,23	0,19	0,23	0,19	0,19
MSE	0,007	0,008	0,010	0,008	0,008

Legend: NE = not evaluated

	VARIATION	l (%) vs T0	
T1h	T6h	T24h	T48h
-22,5%	-13,9%	-27,8%	-26,0%

### **OPTICAL DENSITOMETRY**

### **ERYTHEMA INDEX**

### IDROGEL SOLUZIONE CONTROLLO (prot. 2649)

VOL N.	T0 - BASELINE (immediately after stripping)	T1h (1 hour after product application)	product application)	product application)	T48h (48 hours after product application)
1	0,17	0,14	0,16	0,16	0,17
2	0,16	0,15	0,13	0,12	0,11
3	0,17	0,11	0,12	0,11	0,12
4	0,14	0,09	0,10	0,08	0,08
5	0,22	0,14	0,18	0,16	0,17
6	0,28	0,18	0,22	0,17	0,20
7	0,18	0,19	0,20	0,19	0,19
8	0,21	0,15	0,23	0,20	0,16
9	0,20	0,15	0,15	0,11	0,10
10	0,18	0,14	0,19	0,15	0,18
11	0,20	0,13	0,22	0,14	0,10
12	0,11	0,11	0,14	0,10	0,14
13	0,20	0,15	0,14	0,14	0,14
14	0,18	0,16	0,12	0,09	0,13
15	0,15	0,08	0,16	0,09	0,09
16	0,19	0,13	0,13	0,14	0,13
17	[0,11]	NE	NE	NE	NE
18	0,19	0,16	0,19	0,19	0,16
19	0,11	0,09	0,09	0,07	0,07
20	0,16	0,08	0,11	0,11	0,11
21	0,24	0,17	0,24	0,19	0,18
MEAN	0,182	0,135	0,161	0,136	0,137
ST. DEV.	0,040	0,032	0,045	0,040	0,039
MIN	0,11	0,08	0,09	0,07	0,07
MAX	0,28	0,19	0,24	0,20	0,20
MSE	0,009	0,007	0,010	0,009	0,009

Legend: NE = not evaluated

	VARIATION	√ (%) vs T0	
T1h	T6h	T24h	T48h
-25,9%	-11,5%	-25,3%	-24,7%

## OPTICAL COLORIMETRY - SKIN ERYTHEMA

## LIPOGEL SOLUZIONE P 1% (prot. 2647)

	- 0 1	TO - BASELINE	٧E		T1h		- Louis Common	T6h			T24h			T48h	
VOL N.	(immi)	(immediately after stripping)	after	(1 hour after applicat		product ion)	(6 hours	(6 hours after product application)	oduct )	(24 houl	(24 hours after product application)	roduct 1)	(48 hou ap	(48 hours after product application)	roduct )
<u> </u>	*_	**	*q	*1	*ਲ	p*	*1	***	*a	*	a*	p*	*1	a*	b*
<b>-</b>	67 11	9.14	12.64	66.85	7.43	13,48	65,00	10,34	13,88	65,35	11,11	14,17	89'99	8,54	14,36
2	90.99	11.51	11,11	67,65	5,97	11,51	69,46	5,65	12,16	68,13	5,27	12,59	68,77	5,83	12,64
3	64.41	13.97	12,09	67,29	8,78	12,21	66,40	9,18	12,36	62,89	7,66	13,02	67,38	7,64	12,92
4	65,73	10,44	11,36	67,05	6,62	12,24	65,16	9,70	12,21	62,89	7,05	12,27	65,65	8,88	11,98
5	65.77	13.86	10,46	68,62	7,98	11,00	67,48	9,03	11,25	68,68	8,59	11,70	67,52	8,29	10,88
9	61.24	13.97	16,04	60,07	13,77	13,67	60,80	13,95	15,25	60,19	13,41	14,95	61,06	13,35	15,48
	63.84	12.08	14,43	64,89	8,97	13,96	60,44	15,51	15,19	61,97	11,97	14,34	62,19	11,38	15,03
ω	65.96	13.75	10,79	66,92	8,64	11,35	64,51	11,01	11,71	61,83	15,40	12,83	64,45	11,50	12,92
တ	61.63	17.35	13,06	63,42	10,92	11,60	64,04	11,29	12,01	66,70	8,84	13,42	65,57	90'6	12,45
10	65.67	9.72	13.31	65,68	8,02	13,90	64,88	9,83	14,25	68,48	6,82	14,13	62,89	7.27	14,17
7	61.96	11.67	15,18	62,51	7,29	14,72	62,79	8,25	15,16	63,27	8,46	14,71	63,80	7,81	14,58
12	68.53	10.00	10.47	69,63	7.32	11,11	68,79	7,67	10,99	70,80	6,24	11,50	70,41	5,74	10,90
13	60.18	14.66	11,94	61,64	12,00	12,69	59,48	14,61	12,59	61,75	11,08	13,79	62,88	10,44	13,73
14	66.67	12.43	11.28	66,35	10,44	10,43	66,26	9,23	10,44	67,71	8,50	9,38	68,48	7,37	11,14
5	68.57	06.9	11.51	68,72	5,95	11,53	65,28	9,79	12,04	67,81	6,27	12,39	66,87	6,70	14,21
16	64.31	10.94	14.91	63.15	86.8	14,56	65,17	96'8	14,50	63,37	9,44	15,55	63,11	96'6	14,60
17	[65.98]	[9,19]	[11,29]	Ä	빙	Ä	빌	빙	빙	ЯN	NE	NE	밀	빙	빙
18	59.52	16.54	15.29	62,03	9,92	15,79	59,37	13,64	15,86	62,21	12,92	16,61	60,01	12,09	16,18
19	66,14	9,50	8,30	86,69	6,52	8,56	69,36	6,39	8,44	70,28	5,38	8,28	69,82	5,96	8,54
20	64.31	14.62	12.18	64,51	10,68	11,25	65,46	10,73	11,75	65,58	9,93	13,11	66,68	8,06	13,70
21	62.86	12,81	14,81	61,95	11,07	14,52	63,00	66'6	14,85	61,66	8,16	14,94	63,14	9,60	14,76
MEAN	64.524	12.293	12,558	65,446	8,864	12,504	64,657	10,238	12,845	65,578	9,125	13,184	65,618	8,774	13,259
ST.DEV	2.596	2.617	2,032	2,912	2,125	1,781	3,005	2,581	1,943	3,270	2,791	1,987	2,929	2,158	1,873
Z	59.52	6.90	8.30	60,07	5,95	8,56	59,37	5,65	8,44	60,19	5,27	8,28	60,01	5,74	8,54
MAX	68.57	17.35	16.04	69,98	13,77	15,79	69,46	15,51	15,86	70,80	15,40	16,61	70,41	13,35	16,18
MSE	0.580	0.585	0.454	0,651	0,475	0,398	0,672	0,577	0,434	0,731	0,624	0,444	0,655	0,482	0,419

Legend: NE = not evaluated

## **OPTICAL COLORIMETRY - SKIN ERYTHEMA**

## LIPOGEL SOLUZIONE P 1% (prot. 2647)

		T48h	5,6%	
	þ*	T24h	5,0%	
	q	T6h	2,3%	
		T1h	-0,4%	
LINE		T48h	-28,6%	
% VARIATION vs BASELINE	a*         T1h       T6h       T24h       T48h         -27,9%       -16,7%       -25,8%       -28,6%			
RIATION	ä	-16,7%		
۷۸ %		-27,9%		
		T48h	1,7%	
	*.	T24h	1,6%	
	<b>*</b>	T6h	0,2%	
		T1h	1,4%	

Statistical analysis: Dunnett test p<0,05 T1h, T6h, T24h and T48h vs T0

## **OPTICAL COLORIMETRY - SKIN ERYTHEMA**

## IDROGEL SOLUZIONE B (prot. 2650)

VOL N.	-	TO - BASELINE	Щ		Ę Ę			T6h	HOUSE COMPA		T24h			T48h	
;	(immec	(immediately after	fter	(1 hour after		product	(6 hour	(6 hours after product	oduct	(24 hou	(24 hours after product	roduct	(48 hou	(48 hours after product	product
	str	stripping)		ab	application)		ab	application	)	ac	application		T	appiication)	
	*1	ъ*	<b>p</b> *	<u>*</u> _	**	, a	*	***	p*	*	*c	*q	*1	* *	<u>*</u> 0
1 66	66,33 1	11,49	13,67	66,84	7,86	13,34	63,59	11,28	13,05	65,47	10,37	13,91	66,01	9,05	14,00
2 65		10,40	10,66	67,19	8,41	11,60	68,58	6,43	12,92	68,32	6,25	13,00	67,70	6,29	12,70
3 64	64,51	12,98	13,20	66,35	10,52	13,13	66,23	9,57	13,17	65,93	9,11	12,68	66,72	9,10	12,47
4 66		8,55	10,75	67,44	6,48	11,45	66,64	7,92	11,85	67,51	6,45	11,38	66,89	7,05	11,88
5 64	64,87	13,45	10,74	67,95	8,30	11,30	67,97	7,54	11,33	67,37	8,14	11,61	67,51	7,77	11,19
6 58	58,68	17,82	16,06	59,02	13,10	13,70	60,48	13,34	15,06	61,58	10,96	16,86	59,63	13,09	16,13
7 62	62,57	12,69	13,78	63,07	9,35	13,30	59,55	15,32	13.86	63,01	12,01	14,22	61,18	11,87	14,88
8 66	86,68	9,48	10,57	65,65	9,52	12,56	63,46	11,71	11,65	64,19	11,92	12,51	63,82	11,20	13,76
9 64	64,68	13,41	12,95	63,67	11,38	10,71	65,36	10,46	11,55	64,75	8,62	11,56	67,38	7,41	12,71
10 66	66,73	8,19	13,68	65,75	7,56	14,60	08'99	7,53	12,88	68,18	6,99	12,64	67,26	7,02	12,48
11 60	60,83	12,89	14,65	62,86	7,97	15,13	63,21	7,71	15,23	62,51	8,15	14,31	62,78	7,72	14,54
12 68	68,36	10,51	10,18	70,17	6,65	10,94	67,71	7,89	9,50	69,48	6,30	10,48	68,23	6,62	9,42
13 62	62,10	13,39	10,61	62,88	11,15	12,84	60,17	15,21	12,48	61,75	11,36	12,21	62,73	10,60	13,78
14 63	63,99	15,14	10,88	64,20	12,00	9,73	66,50	09'6	10,46	68,05	7,71	11,27	67,15	8,87	10,48
15 69	00'69	6,65	10,94	68,58	6,26	11,18	64,10	11,87	11,25	68,11	8,06	12,59	66,48	8,13	13,07
_	_	12,80	14,39	63,48	9,36	15,12	63,84	9,58	15,15	64,20	9,13	15,13	64,85	9,32	14,05
17 [66	[66,44]	[7,43]	[10,83]	₩ W	뮏	¥.	빌	빙	NE	NE NE	NE	NE	NE	빙	NE
18 61		11,82	15,12	61,55	10,08	15,56	59,72	12,47	15,47	92'09	12,79	16,10	99'09	12,21	14,37
19 68	98,90	8,02	8,14	69,26	7,12	8,64	69,23	6,45	8,32	70,99	4,85	8,55	69,69	5,94	8,11
	65,23	13,25	12,55	68,16	7,61	13,20	67,70	8,46	13,06	67,71	8,47	13,60	69,38	6,07	13,61
21 61	61,12	11,96	15,08	61,68	10,81	14,88	61,49	11,14	14,87	62,44	8,99	14,78	63,14	9,01	14,50
z	64,567 1	11,745	12,430	65,288	9,075	12,646	64,617	10,074	12,656	65,616	8,832	12,970	65,460	8,717	12,907
ST.DEV 2,	2,836		2,124	2,972	1,965	1,918	3,116	2,681	1,971	2,966	2,173	1,969	2,932	2,131	1,942
-		6,65	8,14	59,02	6,26	8,64	59,55	6,43	8,32	92,09	4,85	8,55	59,63	5,94	8,11
		17,82	16,06	70,17	13,10	15,56	69,23	15,32	15,47	70,99	12,79	16,86	69'69	13,09	16,13
m.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		0,596	0,475	0,665	0,439	0,429	0,697	0,600	0,441	0,663	0,486	0,440	0,656	0,477	0,434

Legend: NE = not evaluated

## **OPTICAL COLORIMETRY - SKIN ERYTHEMA**

## IDROGEL SOLUZIONE B (prof. 2650)

1		*_		¥ > 0′.	RIATION \	% VARIATION vs BASELINE a*			£	*a	
1.	T6h	T24h	T48h	T1h	T6h	T24h	T48h	T1h	T6h	T24h T48h	T48h
. –	0,1%	1,6%	1,4%	-22,7%	-22,7% -14,2% -24,8%	-24,8%	-25,8%	1,7%	1,8%	4,3%	3,8%

Statistical analysis: Dunnett test p<0,05 T1h, T6h, T24h and T48h vs T0

## **OPTICAL COLORIMETRY - SKIN ERYTHEMA**

# LIPOGEL SOLUZIONE CONTROLLO 1% (prot. 2648)

		TO - BASELINE	NE		T1h			T6h			T24h			T48h	
VOL N.	mmi) s	(immediately after stripping)	after	(1 hou	(1 hour after pro application)	product on)	(6 hour ap	(6 hours after product application)	oduct.	(24 hou ap	(24 hours after product application)	oroduct 1)	(48 hou a <u>l</u>	(48 hours after product application)	oroduct n)
	*_	a*	p*	*_	**	*a	*_	*#	*q	*_	*rd	*q	ľ	*E	p*
	66,54	10,91	13,37	65,19	11,19	14,03	64,50	12,81	13,33	62,59	11,53	13,51	65,63	10,20	14,26
2	68,08	8,99	10,97	66,90	7,62	12,14	69,31	5,97	11,56	67,92	6,49	11,47	96'99	6,14	11,10
3	26'99	10,36	12,44	67,17	8,21	11,68	67,49	8,20	12,47	67,75	6,72	12,85	67,45	8,40	13,85
4	63,89	12,43	11,46	65,98	7,74	11,60	64,34	11,12	12,23	65,28	9,63	12,37	64,95	9,90	12,32
5	65,74	12,12	11,71	67,07	8,44	11,04	64,88	9,45	10,87	66,17	80'6	12,20	65,08	9,64	11,80
9	61,07	15,05	15,81	60,25	12,91	14,25	59,20	14,99	14,74	62,42	11,39	16,02	62,60	11,21	15,43
7	63,89	11,49	14,10	63,85	10,82	13,73	58,82	15,46	14,39	61,36	11,11	13,76	60,58	10,58	14,17
8	64,79	12,98	12,30	68,59	88'9	11,86	64,62	10,37	11,99	62,89	11,90	12,73	67,62	7,78	12,82
6	61,39	16,12	12,57	63,72	10,77	11,81	63,28	10,99	12,11	65,71	9,58	13,58	65,36	10,61	13,24
10	64,32	12,53	12,66	65,82	6,33	12,10	63,51	12,34	13,40	00'99	10,41	14,12	64,35	10,89	13,84
11	60,04	13,04	14,22	61,71	9,79	14,37	60,41	10,97	14,29	62,14	9,43	14,29	62,19	95'8	14,82
12	69,61	9,87	9,79	70,10	7,38	9,82	69,18	7,28	10,70	71,34	96'5	11,23	70,22	09'9	10,67
13	60,40	13,09	11,21	62,12	10,88	12,45	59,93	12,76	11,67	63,17	11,56	12,30	61,76	98'6	12,78
14	65,56	10,81	11,56	66,31	9,50	11,16	66,01	8,99	11,49	67,36	6,53	10,96	67,32	8,20	11,61
15	69,92	7,31	11,25	69,40	6,10	11,53	66,10	10,46	11,90	60'69	25'9	12,59	69,03	5,96	13,09
16	64,69	10,13	14,12	64,77	8,39	14,50	64,68	9,35	13,61	62,23	8,54	14,04	62,95	9,40	13,35
17	[67,20]	[7,65]	[10,85]	N	NE	빙	Ш И	NE	NE	JN	]NE	∃N	NE	NE	빌
18	61,58	15,02	14,62	90'89	10,10	15,00	64,01	9,63	15,86	61,72	14,70	15,75	62,20	12,41	16,24
19	67,00	11,35	60'6	68,49	7,89	8,28	68,31	8,05	8,78	68,83	5,65	7,58	69,48	86'9	8,60
20	65,81	10,82	13,22	67,34	7,24	13,02	66,63	8,60	13,37	69'99	8,65	13,91	67,12	8,42	13,74
21	62,25	11,05	13,98	63,77	10,12	14,29	61,36	10,75	13,54	61,65	9,42	13,93	62,89	6,12	14,46
MEAN	64,677	11,774	12,523	65,581	9,065	12,433	64,329	10,427	12,615	65,411	9,243	12,960	65,287	9,043	13,109
ST.DEV	2,913	2,121	1,690	2,667	1,748	1,725	3,146	2,413	1,631	2,880	2,409	1,840	2,806	1,762	1,763
ZIE	60,04	7,31	60'6	60,25	6,10	8,28	58,82	5,97	8,78	61,36	5,65	7,58	60,58	5,96	8,60
MAX	69,92	16,12	15,81	70,10	12,91	15,00	69,31	15,46	15,86	71,34	14,70	16,02	70,22	12,41	16,24
MSE	0,651	0,474	0,378	0,596	0,391	0,386	0,703	0,540	0,365	0,644	0,539	0,411	0,628	0,394	0,394

Legend: NE = not evaluated

## OPTICAL COLORIMETRY - SKIN ERYTHEMA

# LIPOGEL SOLUZIONE CONTROLLO 1% (prot. 2648)

				۷۸ %	RIATION	% VARIATION vs BASELINE	LINE				
		*_			a*	*			q	p*	
T1h	T6h	T24h	T48h	T1h	T6h	T24h	T48h	T1h	T6h	T24h	T48h
1,4%	-0,5%	1,1%	%6'0	0,9% -23,0% -11,4% -21,5% -23,2% -0,7%	-11,4%	-21,5%	-23,2%		%2'0	3,5%	4,7%

Statistical analysis: Dunnett test p<0,05 T1h, T6h, T24h and T48h vs T0

## OPTICAL COLORIMETRY - SKIN ERYTHEMA

# IDROGEL SOLUZIONE CONTROLLO (prot. 2649)

	)		<u>_</u>					_ _			T24h	- Annie		148h	<u> </u>
2	(imm	(immediately after	after	(1 hour after		product	(6 hour	(6 hours after product	oduct	(24 hou	(24 hours after product	roduct	(48 hou	(48 hours after product	roduct
	S	stripping)		аb	application)		ab	application		ਲ	application	_	ak	application	)
	*1	* *o	p*	*	a*	ъ*	*	a*	p*	*	*8	p*	*1	*w	b*
1	62,89	11,75	13,24	62,79	7,71	13,04	65,07	11,33	13,66	66,02	10,75	14,44	64,40	10,05	14,62
2	65,68	11,38	11,06	65,51	9,02	11,13	66,87	7,25	11,61	67,12	99'9	10,81	66,80	6,73	10,72
က	64,81	13,14	13,20	64,93	10,68	13,09	67,23	8,16	13,97	60,99	8,53	14,13	66,13	9,04	13,72
4	62,59	9,18	10,62	67,32	5,29	11,57	66,68	5,74	11,40	68,85	4,97	12,73	67,57	5,56	11,92
5	63,90	15,52	12,56	66,45	9,49	11,93	63,42	13,28	12,29	6,27	10,40	13,20	64,45	11,89	13,16
9	59,58	17,42	15,44	58,71	13,99	14,21	60,48	13,48	14,01	61,37	12,16	15,49	62,51	10,90	14,87
7	63,24	11,95	13,56	61,69	11,67	13,24	59,31	14,45	13,07	62,58	11,98	13,91	60,24	12,24	13,71
8	68,12	8,80	12,13	96'.29	7,56	10,95	62,22	14,28	10,60	64,12	13,22	11,79	66,65	10,80	13,15
6	62,17	15,42	12,50	62,46	10,46	11,48	64,61	11,06	12,04	66,53	8,09	13,30	66,64	8,94	12,84
10	66,29	10,13	11,56	65,63	8,38	13,36	63,99	11,74	14,43	64,95	10,12	14,35	64,49	9,27	13,89
11	59,17	14,31	14,17	59,87	11,08	15,08	59,03	12,41	14,75	62,37	8,75	17,10	62,88	7,87	15,35
12	68,36	11,30	10,64	69,73	6,39	10,48	66,85	9,10	10,31	69,27	7,47	11,31	69,12	7,82	12,03
13	61,55	12,29	11,80	61,92	80'6	10,97	61,44	12,69	12,64	63,32	8,59	12,31	63,69	7,44	12,26
4	65,47	13,30	10,94	65,34	10,60	9,71	67,40	8,27	10,41	68,66	5,33	11,80	66,97	8,22	10,51
15	69,33	7,03	10,95	66,39	5,68	11,45	66,39	9,14	11,28	69,42	6,35	12,16	68,34	5,99	12,14
16	64,25	11,36	15,25	65,18	8,84	14,87	63,86	00'6	13,79	63,23	8,34	14,03	64,06	9,91	14,95
17	[65,39]	[90,7]	[11,45]	빌	빙	ШХ	NE	NE	NE	NE	NE	NE	빌	빙	빙
18	62,85	11,82	14,20	63,46	89'6	14,91	63,08	9,53	15,26	61,71	12,80	15,65	61,59	11,96	15,09
19	68,80	8,26	7,87	06'89	6,85	8,94	68,72	7,36	8,89	70,42	4,53	8,65	69,31	6,64	7,89
20	66,84	11,38	13,95	68,50	6,97	14,05	67,60	8,02	14,24	65,43	10,15	14,51	62,99	9,41	14,25
21	62,67	12,05	13,64	62,45	10,99	14,07	60,09	13,75	13,35	61,80	12,58	14,63	63,62	10,62	15,44
MEAN	64,728	11,890	12,464	65,150	9,021	12,427	64,217	10,502	12,600	62,477	680'6	13,315	65,273	9,065	13,126
ST.DEV	2,882	2,552	1,839	3,196	2,213	1,809	3,012	2,663	1,737	13,534	2,691	1,932	2,482	2,007	1,917
NE	59,17	7,03	7,87	58,71	5,29	8,94	59,03	5,74	8,89 89	6,27	4,53	8,65	60,24	5,56	7,89
MAX	69,33	17,42	15,44	69,73	13,99	15,08	68,72	14,45	15,26	70,42	13,22	17,10	69,31	12,24	15,44
MSE	0,644	0,571	0,411	0,715	0,495	0,405	0,673	0,595	0,388	3,026	0,602	0,432	0,555	0,449	0,429

Legend: NE = not evaluated

## OPTICAL COLORIMETRY - SKIN ERYTHEMA

# IDROGEL SOLUZIONE CONTROLLO (prot. 2649)

% VARIATION vs BASELINE  a*  T1h T6h T24h T48h T1h  -24,1% -11,7% -23,6% -23,8% -0,3%		L* T6h T24h T48h -0,8% -3,5% 0,8% -
---	--	-------------------------------------

Statistical analysis: Dunnett test p<0,05 T1h, T6h, T24h and T48h vs T0

### SKIN ERYTHEMA LIPOGEL SOLUZIONE P 1% (prot. 2647)

VOL N.	T0 - BASELINE (immediately after stripping)	T1h (1 hour after product application)	T6h (6 hours after product application)	T24h (24 hours after product application)	T48h (48 hours after product application)
1	1,0	1,0	1,5	1,0	1,0
2	1,5	0.5	0,0	0,0	0,0
3	1,5	0.5	0.5	0,0	0,0
4	2,0	0.5	1,5	1,0	1,0
5	1,5	0,0	0.5	0.5	0.5
6	1,5	0.5	0.5	0.5	0,0
7	1,5	1,5	2,0	1,5	1,0
8	2,0	0.5	1,5	1,5	1,0
9	2,0	1,0	1,0	0,0	0,0
10	1,0	0.5	1,0	0.5	0.5
11	1,0	0,0	0,0	0,0	0,0
12	1,5	0.5	0.5	0,0	0,0
13	1,5	2,0	2,0	1,5	1,0
14	1,5	1,0	0.5	0.5	0,0
15	1,0	0.5	1,5	1,0	0.5
16	1,0	0.5	0.5	0,0	0,0
17	[1,0]	NE	NE	NE	NE
18	1,5	1,0	1,0	1,5	0.5
19	1,5	0.5	0.5	0,0	0,0
20	2,0	1,0	1,0	0.5	0.5
21	1,5	1,0	0.5	0.5	0,0
MEAN	1,48	0,95	1,17	0,64	0,33
ST. DEV.	0,343	0,599	0,651	0,691	0,488
MIN	1,00	0,00	0,00	0,00	0,00
MAX	2,00	2,00	2,00	1,50	1,00
MSE	0,077	0,189	0,188	0,185	0,126

LEGEND:

0= no erythema

1,5= moderate erythema

0,5= very slight erythema

2= severe erythema

1= well defined erythema

NE = not evaluated

	VARIATIO	N (%) vs T0	
T1h	T6h	T24h	T48h
-35,8%	-20,9%	-56,4%	-77,7%

			SUBJE	CTS %	
		T1h	T6h	T24h	T48h
þ	0,5 grades	15%	20%	5%	10%
Improved	1 grade	30%	20%	20%	30%
pro	1,5 grades	30%	40%	40%	45%
<u>=</u>	2 grades	10%	0%	0%	10%
	Not changed	10%	5%	25%	5%
	Worsened	5%	15%	10%	0%

### SKIN ERYTHEMA IDROGEL SOLUZIONE B (prot. 2650)

VOL N.	T0 - BASELINE (immediately after stripping)	T1h (1 hour after product application)	T6h (6 hours after product application)	T24h (24 hours after product application)	T48h (48 hours after product application)
1	1,5	0.5	1,5	1,0	1,0
2	1,5	1,5	0.5	0,5	0.5
3	1,5	0.5	0.5	0,0	0,0
4	1,5	0.5	1,0	0.5	0.5
5	2,0	0,0	0,0	0,0	0,0
6	2,0	0.5	0,0	0,0	0,0
7	2,0	2,0	1,5	1,5	1,0
8	1,5	1,0	1,5	1,0	1,0
9	1,5	1,0	1,0	0,0	0,0
10	1,0	0.5	0.5	0.5	0,0
11	1,5	0.5	0,0	0,0	0,0
12	1,5	0.5	0.5	0,0	0,0
13	1,5	2,0	2,0	1,5	1,0
14	2,0	1,5	1,0	0.5	0,0
15	2,0	2,0	2,0	1,5	1,0
16	1,5	0.5	0.5	0,0	0,0
17	[0.5]	NE	NE	NE	NE
18	1,5	1,0	1,0	1,5	0.5
19	1,5	0.5	0,0	0,0	0,0
20	2,0	0,0	0.5	0,0	0,0
21	1,5	1,0	0.5	0.5	0,0
MEAN	1,63	1,18	0,96	0,53	0,29
ST. DEV.	0,275	0,717	0,749	0,670	0,470
MIN	1,00	0,00	0,00	0,00	0,00
MAX	2,00	2,00	2,00	1,50	1,00
MSE	0,062	0,216	0,208	0,168	0,114

LEGEND:

0= no erythema

1,5= moderate erythema

0,5= very slight erythema

2= severe erythema

1= well defined erythema

NE = not evaluated

		N (%) vs T0	
T1h	T6h	T24h	T48h
-27,6%	-41,1%	-67,5%	-82,2%

			SUBJE	CTS %	
		T1h	T6h	T24h	T48h
ved	0,5 grades	25%	20%	20%	15%
Š	1 grade	5%	10%	10%	15%
Impro	1,5 grades	35%	35%	40%	50%
<u>E</u>	2 grades	15%	15%	20%	20%
	Not changed	15%	15%	10%	0%
	Worsened	5%	5%	0%	0%

### SKIN ERYTHEMA LIPOGEL SOLUZIONE CONTROLLO 1% (prot. 2648)

VOL N.	T0 - BASELINE (immediately after stripping)	T1h (1 hour after product application)	T6h (6 hours after product application)	T24h (24 hours after product application)	T48h (48 hours after product application)
1	1,5	1,5	2,0	1,5	1,5
2	1,0	1,0	0,0	0,0	0,0
3	1,0	0.5	0.5	0,0	0,0
4	2,0	1,0	1,5	1,5	1,5
5	1,5	0,0	1,0	1,0	1,0
6	1,5	0.5	0,0	0,0	0,0
7	1,5	1,5	2,0	1,5	1,0
8	2,0	0.5	1,0	1,0	0.5
9	2,0	1,0	1,0	0,0	0,0
10	1,0	1,0	1,5	1,0	1,0
11	1,5	0.5	0.5	0.5	0,0
12	1,5	0.5	0,0	0,0	0,0
13	1,5	1,0	1,0	1,0	0.5
14	2,0	1,0	0.5	0,0	0,0
15	1,5	0.5	1,5	0.5	0,0
16	1,0	0.5	0.5	0,0	0,0
17	[0.5]	NE	NE	NE	NE
18	1,5	1,0	1,5	1,0	0.5
19	1,5	0.5	0.5	0,0	0,0
20	2,0	0,0	0.5	0.5	0.5
21	1,5	1,0	0.5	0.5	0,0
MEAN	1,53	0,92	1,08	0,59	0,38
ST. DEV.	0,343	0,469	0,703	0,638	0,592
MIN	1,00	0,00	0,00	0,00	0,00
MAX	2,00	1,50	2,00	1,50	1,50
MSE	0,077	0,135	0,195	0,160	0,148

LEGEND:

0= no erythema

1,5= moderate erythema

0,5= very slight erythema

2= severe erythema

1= well defined erythema

NE = not evaluated

	VARIATIO	N (%) vs T0	
T1h	T6h	T24h	T48h
-39,9%	-29,4%	-61,4%	-75,2%

			SUBJE	CTS %	
	<del></del>	T1h	T6h	T24h	T48h
D.	0,5 grades	15%	15%	20%	15%
Improved	1 grade	25%	25%	20%	15%
pro	1,5 grades	30%	25%	30%	40%
트	2 grades	10%	10%	15%	20%
	Not changed	20%	10%	15%	10%
	Worsened	0%	15%	0%	0%

### SKIN ERYTHEMA IDROGEL SOLUZIONE CONTROLLO (prot. 2649)

VOL N.	T0 - BASELINE (immediately after stripping)	T1h (1 hour after product application)	T6h (6 hours after product application)	T24h (24 hours after product application)	T48h (48 hours after product application)
1	1,5	0.5	1,5	1,5	1,5
2	1,5	2,0	1,0	0,5	0.5
3	1,5	0.5	0.5	0.5	0,0
4	2,0	0.5	0.5	0.5	0,0
5	2,0	1,0	1,5	1,0	1,5
6	2,0	0,0	0,0	0,0	0,0
7	1,5	1,5	1,5	1,5	1,0
8	2,0	1,0	1,5	1,5	1,0
9	1,5	1,0	1,0	0,0	0.5
10	1,0	0.5	1,5	1,0	1,0
11	2,0	0.5	1,0	0.5	0,0
12	1,0	1,0	1,0	0,0	0.5
13	1,5	1,0	1,0	0.5	0,0
14	2,0	1,0	0,0	0,0	0,0
15	1,5	0.5	1,5	0.5	0,0
16	1,5	0.5	0.5	0,0	0,0
17	[0.5]	NE	NE	NE	NE
18	1,5	1,0	1,5	1,5	0.5
19	2,0	0.5	0,0	0,0	0,0
20	2,0	0,0	0.5	0.5	0.5
21	1,5	1,0	1,5	2,0	0.5
MEAN	1,65	0,96	1,06	0,75	0,43
ST. DEV.	0,328	0,542	0,574	0,753	0,616
MIN	1,00	0,00	0,00	0,00	0,00
MAX	2,00	2,00	1,50	2,00	1,50
MSE	0,073	0,156	0,143	0,201	0,165

LEGEND:

0= no erythema

1,5= moderate erythema

0,5= very slight erythema

2= severe erythema

1= well defined erythema

NE = not evaluated

		N (%) vs T0	
T1h	T6h	T24h	T48h
-41,8%	-35,8%	-54,5%	-74,0%

			SUBJE	CTS %	
		T1h	T6h	T24h	T48h
ved	0,5 grades	20%	25%	5%	10%
Š	1 grade	20%	5%	15%	10%
Impro	1,5 grades	20%	10%	25%	40%
	2 grades	25%	25%	30%	30%
	Not changed	10%	30%	20%	10%
	Worsened	5%	5%	5%	0%

-19,8% T48h

-13,4% T24h

3,8% T6h

### **INSTRUMENTAL EVALUATION**

### SKIN ELECTRICAL CAPACITANCE (SKIN SURFACE HYDRATION) LIPOGEL SOLUZIONE P 1% (prof. 2647)

_																									ç	<b>-</b>	T48h	-11,1%	vs T1h
	V	(T48h-T0)	-20,6	-4,1	-10,3	4,7	-11,4	-16,4	-46,6	10,3	-2,8	-14,2	7,9	1,0	-14,1	-4,3	4,6	2,6	1	6,1	-3,0	1,9	-11,1		T 02. ( /0/ IA	OL SV (%) NOTHERNA	T24h	-4,0%	VARIATION (%) vs T1h
	V	(T24h-T0) (T48h-T0)	-2,0	-5,1	5,5-	16,8	-7,0	-3,8	-32,2	9'9	-1,5	-4,9	11,2	6,3-	-10,8	3,5	-1,0	3,5	•	1,7	<b>5'</b> 5-	9' <i>L</i>	-1111		OT VIO V/V	אואא	U91	14,9%	VARI
	Δ	(T6h-T0)	17,3	13,1	2,8	30,6	9,0	-10,7	-4,6	24,9	7'0-	5,5	6,9	8,0	-2,1	11,6	6,4	3,2	1	20,0	12,4	10,8	4,9				T1h	10,8%	
	∇	(T1h-T0)	9,5	12,9	8,9-	24,4	-13,1	-2,5	-7,5	3,9	-15,8	-2,3	27,0	13,1	5,3	6,2	12,6	12,8	t	16,3	10,9	2,1	7,0						
,	T48h (48 hours after	product application)	37,9	40,0	43,8	48,1	48,9	46,5	30,3	57,9	6'99	47,4	50,0	45,1	43,5	40,9	49,5	51,5	NE NE	64,0	41,7	50,5	52,8	47,86	8,515	30,30	06'99	1,904	
	T24h (24 hours after	product application)	56,5	39,0	50,8	60,2	53,3	59,1	44,7	54,2	68,2	56,7	53,3	37,8	46,8	48,7	43,9	52,4	NE	59,6	39,2	56,2	52,8	51,67	7,939	37,80	68,20	1,775	
	T6h (6 hours after	product application)	75,8	57,2	6'99	74,0	6'09	52,2	72,3	72,5	69,0	67,1	49,0	52,1	55,5	56,8	51,3	52,1	NE	77,9	57,1	59,4	68,8	61,90	9,320	49,00	77,90	2,084	
	T1h (1 hour after	product application)	68,0	57,0	47,3	67,8	47,2	60,4	69,4	51,5	53,9	59,3	69,1	57,2	62,9	51,4	57,5	61,7	- IN	74,2	55,6	50,7	70,9	59,65	8,154	47,20	74,20	1,823	
	TO - BASELINE	(Immediately after stripping)	58,5	44,1	54,1	43,4	60,3	62,9	6'9/	47,6	2'69	61,6	42,1	1,44	57,6	45,2	44,9	48,9	[52,1]	57,9	44,7	48,6	63,9	53,85	9,964	42,10	06'92	2,228	not evaluated
	3		1	2	3	4	5	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	MIN	MAX	MSE	l egend: NF = not evaluated

p<0,05 T24h and T48h vs T1h and T6h Statistical analysis: Tukey test p<0,05 T6h vs T0

**T48h** -24,2%

**T24h** -16,0%

**T6h** 

VARIATION (%) vs T1h

## INSTRUMENTAL EVALUATION

# SKIN ELECTRICAL CAPACITANCE (SKIN SURFACE HYDRATION) IDROGEL SOLUZIONE B (prot. 2650)

Parties de la constant de la constan				-		-	<del></del>	<b>****</b>				· Athqua			- حنور ۱											0	ТЛЯН	-13.5%
	∇	(T48h-T0)	C 11C	C,C2-	0,6,7	- ' ' '	χ.	-14,U	22.0	6,22-	0,0	1,0	C,C-	r α	ָרְ ס ס	2,0	2 2	000	). )	5.9	-3.1	8.4	-196	1.0		L sv (%) N	T24h	-4,1%
	۵	(T24h-T0)	7 0 7	10,4	40,0	0,0	4.0.4	C,4 -	1 7	11,1	2,0	2,7	200	λ. α. π.	5,0	1.4	1,1	-7.7		6.4	-1.7	6.5	-8.4			VARIATION (%) vs T0	Тбһ	6,2%
The Water Control of the Control of	٧	(T6h-T0)	n G	ס מ	0,0	12,0	6,71	0,0	4.5	λα,	γ α	-5.7	3.1	2.2	191	16.9	30.5	2,2	) i	15.4	1,4	18.9	-7.2				T1h	14,2%
	٧	(T1h-T0)	Cα	12.2	5,0	, L	2,0	2,4	18.3	23.7	4.5	0,0	13.0	0.7	89	6.4	111	119		18,3	1,4	18,2	-6.2		<b>-</b>	em 5	<u>'</u>	
T48h	(48 hours after	product application)	35.7	34.4	32.0	53.0	20,0	42.7	31.9	414	615	49.7	44.8	42.6	54.5	43.9	51.3	55,1	ШN	62,3	46,7	56,3	46,2	46.56	9.043	31.90	62.30	2,022
T24h	(24 hours after	product application)	50.6	32.2	38.5	517	43.7	54.9	50,4	64.7	69.1	58,6	46,4	38,9	55,0	49,5	60,4	44,5	UZ	62,8	48,1	54,4	57,4	51,59	9,352	32,20	69,10	2,091
T6h	(6 hours after	product application)	9,99	49.8	39.3	69.4	48.9	56.4	59,3	66,0	57,1	48,5	43,1	49,6	62,3	64,7	59,0	54,5	NE	71,8	51,2	8,99	58,6	57,15	8,981	39,30	71,82	2,008
T1h	(1 hour after	product application)	0,69	57,3	49,0	57.4	54.6	52,9	73,1	71,6	70,4	61,8	59,2	48,1	67,2	54,2	67,1	64,1	N	74,7	51,2	66,1	59,6	61,43	8,266	48,10	74,70	1,848
IN BASELINE	(immediately	after stripping)	61,0	44,0	49,1	52,1	58,2	59,5	54,8	47,9	62,9	53,6	46,2	47,4	60,4	47,8	56,0	52,2	[47,4]	56,4	49,8	47,9	65,8	53,80	6,465	44,00	65,90	1,446
	VOL N.			2	က	4	5	9	7	8	6	10	11	12	13	14	15	16	17	ω.	19	20	21	MEAN	ST. DEV.	ZΙΣ	MAX	MSE

Legend: NE = not evaluated

Statistical analysis: Tukey test p<0,05 T1h and T48h vs T0 p<0,05 T24h and T48h vs T1h and T6h

-19,6% T48h

6,7% T6h

T24h -6,2%

### INSTRUMENTAL EVALUATION

### SKIN ELECTRICAL CAPACITANCE (SKIN SURFACE HYDRATION) LIPOGEL SOLUZIONE CONTROLLO 1% (prot. 2648)

																											T48h	-15,1%	; T1h
	◁	(T48h-T0)	-46,7	-2,2	-12,2	-19,9	-11,4	-14,4	-34,9	3,4	-6,4	-25,1	-0,7	7,4-	-5,1	-3,6	11,3	12,4	I	-10,3	7.7	8,8	-8,3		OT 21. ( /0/ I	01 80 (0/)	T24h	-1,0%	VARIATION (%) vs T1h
ľ	◁	(T24h-T0) (T48h-T0)	6,9-	8,0	-5,8	3,0	-8,1	-11,7	-0,7	9,0	-3,6	-2,1	6,8	-9,2	6,1-	7,1	10,4	4,1		7,4	9,2	2,8	-17,8		ACITAIGAN	VANIALION (70) VS 10	T6h	12,6%	VARIA:
	ಶ	<u>(</u>	4,5	12,7	9'0-	10,2	10,4	-2,4	15,1	14,4	-3,7	4,7	10,2	5,6	-1,6	13,3	12,4	8,1	•	-11,5	10,7	14,2	13,5				T1h	5,6%	
	∇	(T1h-T0)	-11,6	0,1	2,3	7,5	-1,11	8,0	-9,1	2,3	-23,9	-4,4	20,6	8,7	7,8	8,2	16,3	5,8	•	8,4	14,6	7.4-	13,2						_
	T48h (48 hours after	product application)	34,6	39,3	35,3	42,8	47,6	45,6	30,8	54,1	59,9	38,4	6'05	44,8	41,8	39,7	53,3	62,9	NE	63,0	46,1	57,2	54,3	47,12	9,542	30,80	63,00	2,134	
	T24h (24 hours after	product application)	74,4	42,3	41,7	59,7	50,9	48,3	65,0	59,7	62,7	61,4	60,5	40,3	45,0	50,4	52,4	54,6	NE	80,7	47,6	56,2	44,8	54,93	10,799	40,30	80,70	2,415	
	T6h (6 hours after	product application)	85,8	54,2	46,9	72,9	69,4	57,6	80,8	65,1	62,6	68,2	61,8	55,1	45,3	56,6	54,4	58,6	NE	61,8	49,1	67,6	76,1	62,50	10,923	45,30	85,80	2,442	
No. of the last of	T1h (1 hour after	product application)	69,7	41,6	52,8	70,2	47,9	68,0	9'99	53,0	42,4	59,1	72,2	58,2	54,7	51,5	58,3	56,3	NE	81,7	53,0	48,7	75,8	58,59	10,993	41,60	81,70	2,458	
	T0 - BASELINE	after stripping)	81,3	41,5	47,5	62,7	59,0	0'09	65,7	50,7	66,3	63,5	51,6	49,5	46,9	43,3	42,0	50,5	[54,3]	73,3	38,4	53,4	62,6	55,49	11,386	38,40	81,30	2,546	100to 1000 +00
	3		1	2	3	4	5	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	MIN	MAX	MSE	botoutovo toa - DIA :baobo -

Legend: NE = not evaluated

p<0,05 T24h vs T6h and T48h Statistical analysis: Tukey test p<0,05 T48h vs T0

p<0,05 T48h vs T1h and T6h

-29,2% T48h

-19,7% T24h

-4,3% T6h

### INSTRUMENTAL EVALUATION

### SKIN ELECTRICAL CAPACITANCE (SKIN SURFACE HYDRATION) IDROGEL SOLUZIONE CONTROLLO (prot. 2649)

																										<b>5</b>	T48h	-15,8%	/s T1h
	abla	(T48h-T0)	-42,1	-10,3	-8.7	-5,7	-32,6	-13,5	-22,1	-10,3	-13,8	8,6	-12,4	-7,2	-3,7	2,9	20,1	7,7	1	4,1	10,3	-1,4	-19,9	Standard Control of the Control of t	F 60. ( /0) 14	OLSA (%) NOTIFIED	T24h	-4,4%	VARIATION (%) vs T1h
	Q	(T24h-T0) (T48h-T0)	-13,8	-11,1	2,6	-5,1	-18,9	-14,2	-3,5	2,4	-5,2	-9,2	-12,9	-6,0	3,1	6,4	13,9	3,5	2	11,6	9,7	9,3	6,6-				T6h	13,9%	VARIA
	Δ	(T6h-T0)	3,7	30,2	4,9	5,5	-0,4	-3,9	7,7	4,0	-9,5	1,9	-1,7	10,5	16,5	10,2	14,8	13,9	r	9,9	6'8	16,5	10,4		***************************************		17	19,0%	
	∇	(T1h-T0)	3,6	26,0	11,7	4,3	2,4	8,3	0,3	1,0	-10,9	6,3	15,4	15,2	19,5	8'8-	31,7	15,5	E	16,0	11,7	22,4	10,3						
Secretary continues and the se	T48h (48 hours after	product application)	32,4	32,5	33,5	44,7	35,3	42,4	42,0	57,4	57,9	44,0	40,8	41,8	44,6	49,6	58,4	58,8	ШИ	62,1	44,6	44,5	47,9	45,76	9,140	32,40	62,10	2,044	
	T24h (24 hours after	product application)	60,7	31,7	44,8	45,3	49,0	41,7	9'09	70,1	66,5	44,6	40,3	43,0	51,4	53,1	52,2	54,6	ШZ	72,3	44,0	55,2	6,73	51,95	10,547	31,70	72,30	2,358	
	T6h (6 hours after	product application)	78,2	73,0	1,74	55,9	67,5	52,0	71,8	7,17	62,2	55,7	51,5	59,5	64,8	6'99	53,1	02'0	NE	67,3	43,2	62,4	78,2	61,85	9,961	43,20	78,20	2,227	
	T1h (1 hour after	product application)	78,1	68,8	53,9	54,7	70,3	64,2	64,4	68,7	8,09	60,1	68,6	64,2	67,8	42,9	70,0	9,99	NE	76,7	46,0	68,3	78,1	64,66	9,501	42,90	78,10	2,125	
	To - BASELINE	after stripping)	74,5	42,8	42,2	50,4	6,79	55,9	64,1	67,7	7.17	53,8	53,2	49,0	48,3	46,7	38,3	51,1	[47,2]	2'09	34,3	45,9	67,8	54,32	11,587	34,30	74,50	2,591	not evaluated
	3	, , , , , , , , , , , , , , , , , , ,	<b>Y</b>	7	င	4	5	9		8	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	MIN	MAX	MSE	egend: NF = not evaluated

p<0,05 T24h and T48h vs T1h and T6h Statistical analysis: Tukey test p<0,05 T1h, T6h and T48h vs T0

-2,3%

3,3%

1,2%

0,5%

### INSTRUMENTAL EVALUATION

### DEEP SKIN HYDRATION (1,5 mm) LIPOGEL SOLUZIONE P 1% (prot. 2647)

																									c	<b>.</b>	T48h
Δ (T48h-T0)	-4,2	-1,6	-2,0	2,2	1,8	-4,2	-3,6	0,2	-1,9	-2,2	0,2	-5,5	0,4	-2,0	1,8	3,0	3	1,4	2,9	-2,3	2'0-				T 27. 1 /0/ IA	VARIATION (%) VS 10	T24h
^ ^ ^ (T24h-T0)	2,6	4,3	1,0	7,1	6,0	-3,4	9,2	5,5	-0,4	2,7	-1,1	-3,7	1,6	-0,5	-1,6	8,1-	1	5,6	1,3	-2,4	-3,4					מו אועא	T6h
۵ (T6h-T0)	0,0	4,3	0,1	-0,3	-0,3	-3,2	8,9	-0,3	-0,4	2,5	-2,6	-2,0	1,3	-0,3	2,0	2,2	-	1,7	1,8	-2,3	L' <b>7</b> -						411
Δ (T1h-T0)	5,0	1,8	-0,1	0,5	1,8	0,0	<b>5</b> '0-	-0,3	-3,2	0,2	-1,3	-1,7	0,0	-0,3	1,0	6,2	,	-1,9	2,7	0,0	-1,6						
T48h (48 hours after product application)	39,8	29,1	33,5	34,2	32,5	32,5	33,6	36,9	38,0	34,5	31,1	29,9	36,2	35,0	36,9	40,0	NE	35,8	31,6	34,8	32,5	34,42	3,003	29,10	40,00	0,672	
T24h (24 hours after product application)	46,6	35,0	36,5	39,1	31,6	33,3	46,4	42,2	39,5	39,4	29,8	31,7	37,4	36,5	33,5	35,2	NE	40,0	30,0	34,7	29,8	36,41	5,000	29,80	46,60	1,118	
T6h (6 hours after product application)	44,0	35,0	35,6	31,7	30,4	33,5	46,1	36,4	39,5	39,2	28,3	33,4	37,1	36,7	37,1	2'68	JN	36,1	30'2	34,8	28,5	35,66	4,649	28,30	46,10	1,040	
T1h (1 hour after product application)	44,5	32,5	35,4	32,5	32,5	36,7	36,7	36,4	36,7	36,9	29,6	33,7	35,8	36,7	36,1	43,2	NE	32,5	31,4	37,1	31,6	35,43	3,684	29,60	44,50	0,824	
T0 - BASELINE (immediately after stripping)	44,0	30,7	35,5	32,0	30,7	36,7	37,2	36,7	6'68	36,7	30,9	35,4	35,8	37,0	35,1	37,0	[36,7]	34,4	28,7	37,1	33,2	35,24	3,532	28,70	44,00	06,790	
VOL N.	1	2	3	4	5	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	MIN	MAX	MSE	

Legend: NE = not evaluated

-5,9%

-3,2%

-1,6%

### INSTRUMENTAL EVALUATION

### DEEP SKIN HYDRATION (1,5 mm) IDROGEL SOLUZIONE B (prot. 2650)

																											<b>.</b>	T48h
⊲	(T48h-T0)	-6,2	-3,5	-2,8	9,0	-0,1	-4,2	-10,3	0,5	-1,0	-0,5	-1,1	1,4	-5,6	-2,1	-3,6	0,2	1	4,2	1,5	6'0-	-2,9				F 67. 1/0/ N	- SA (%) N	T24h
۵	(T24h-T0)	2'0-	2,0	-2,8	4,2	-1,2	-3,2	2,9	4,6	0,0	6'0	0,1	-1,8	-6,5	-1,7	-3,0	-0,4	1	12,9	9'0-	-0,4	-4,5				CITAIGAY	VARIATION (%) VS TO	T6h
٧	(T6h-T0)	-2,5	2,0	-3,8	-1,5	-1,3	-3,2	1,5	1,0	1,6	-1,6	-1,9	-1,5	-3,9	-2,7	9'0-	9'0	-	1,2	-1,6	-1,7	-3,0						T1h
4	(T1h-T0)	-1,1	-1,3	-1,3	9,0	6'0	0'0	-1,3	1,0	2,0	0,0	-0,1	-3,7	-4,0	0,4	9'0-	0,2	ı	0'0	-0,7	-1,7	-0,8						
T48h (48 hours after	product application)	36,1	30,3	33,5	31,7	28,6	32,5	32,7	37,4	36,9	35,2	28,6	31,6	39,1	34,2	36,1	36,7	NE	36,7	30,9	35,8	28,6	33,66	3,227	28,60	39,10	0,721	
T24h (24 hours after	product application)	41,6	35,8	33,5	35,3	27,5	33,5	45,9	41,5	37,9	36,6	29,8	33,9	38,2	34,6	36,7	36,1	NE	45,4	28,8	36,3	27,0	35,80	5,229	27,00	45,90	1,169	
T6h (6 hours after	product application)	39,8	35,8	32,5	29,6	27,4	33,5	44,5	37,9	39,5	34,1	27,8	34,2	40,8	33,6	39,1	37,1	NE	33,7	27,8	35,0	28,5	34,61	4,817	27,40	44,50	1,077	
T1h (1 hour after	product application)	41,2	32,5	35,0	31,7	29,6	36,7	41,7	37,9	39,9	35,7	29,6	32,0	40,7	36,7	39,1	36,7	NE	32,5	28,7	35,0	30,7	35,18	4,120	28,70	41,70	0,921	
T0 - BASELINE	(Immediately after stripping)	42,3	33,8	8'98	31,1	28,7	36,7	43,0	36,95	37,9	2,35,7	29,7	35,7	44,7	36,3	39,7	36,5	[36,8]	32,5	29,4	36,7	31,5	35,76	4,477	28,70	44,70	1,001	
Ş	, ,	1	2	3	4	5	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	MIN	MAX	MSE	

Legend: NE = not evaluated Statisti

Statistical analysis: Dunnett test p<0,05 T48h vs T0

-2,8%

4,3%

0,2%

-1,1%

### INSTRUMENTAL EVALUATION

### DEEP SKIN HYDRATION (1,5 mm) LIPOGEL SOLUZIONE CONTROLLO 1% (prot. 2648)

																									٠		T48h
∆ (T48h-T0)	-2,4	-5,0	7,	2,9	-2,8	0,5	-2,7	1,5	6,0-	-3,7	-2,9	-0,4	-0,5	-2,3	-2,0	3,9	1	-0,2	2'0-	6'0-	-0,7				T 01. (/0/ IA	VARIATION (%) VS 10	T24h
^ (T24h-T0)	4,5	-0,3	0,3	4,9	-1,8	-0,9	8,2	6,1	1,5	5,8	-2,8	0,5	4,1	-3,0	-1,2	-0,1	•	2,9	-1,2	3,2	0,4				CITAIGAY	אאאי	T6h
<sup>ا</sup> (T6h-T0)	1,7	-0,3	-0,5	2,7	-2,8	0,5	6,8	0,4	7,0	-1,6	-4,1	0,4	5,1	6'0	0,1	-3,4	1	-3,5	2'0	9,0	0,3						411
<sup>∆</sup> (T1h-T0)	1,7	-2,4	7.4-	2,5	-2,0	0,5	-3,2	1,1	0,0	0,1	-1,6	6,0	3,1	6,0	6'0-	0'0	1	5'8-	2,0	-3,0	1,7						
T48h (48 hours after product application)	44,0	33,2	35,3	35,0	32,5	33,5	37,2	36,8	35,8	33,5	31,7	36,3	34,5	34,0	35,0	44,7	NE	35,8	29,1	37,9	31,6	35,37	3,730	29,10	44,70	0,834	
T24h (24 hours after product application)	50,9	37,9	36,7	37,0	33,5	32,1	48,1	41,4	38,2	43,0	31,8	37,2	39,1	33,3	35,8	40,7	ШN	6'88	28,6	42,0	32,7	37,95	5,480	28,60	20,90	1,225	
T6h (6 hours after product application)	48,1	37,9	35,9	34,8	32,5	33,5	46,7	35,7	37,4	35,6	30,5	37,1	40,1	37,2	37,1	37,4	ШZ	32,5	30,5	35,8	32,6	36,45	4,529	30,50	48,10	1,013	
T1h (1 hour after product application)	48,1	35,8	31,7	34,6	33,3	33,5	36,7	36,4	36,7	37,3	33,0	37,2	38,1	36,6	36,1	40,8	ШZ	32,5	31,8	35,8	34,0	36,00	3,667	31,70	48,10	0,820	
T0 - BASELINE (immediately after stripping)	46,4	38,2	36,4	32,1	35,3	33,0	39,9	35,3	36,7	37,2	34,6	36,7	35,0	36,3	37,0	40,8	[35,9]	36,0	29,8	38,8	32,3	36,39	3,554	29,80	46,40	0,795	
VOL N.	_	2	3	4	5	9	7	8	6	10	1	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	NIM	MAX	MSE	

Legend: NE = not evaluated

T48h

T6h

T1h

-3,5%

5,7%

-0,7%

0,7%

### INSTRUMENTAL EVALUATION DEEP SKIN HYDRATION (1,5 mm)

DEEP SKIN HYDRATION (1,5 mm)
IDROGEL SOLUZIONE CONTROLLO (prot. 2649)

																										5
Δ (T48h-T0)	0'0	43	1,1	0.2	-3.4	-2.9	-1.9	-0.7	-18	-3.9	-3.1	-1.7	-1.8	6'0-	-4.2	-0.2	1	3,9	-0,1	0,7	9.0-					Sv (%) N
Δ (T24h-T0)	4,2	5,2	0,5	-2,3	-0.5	-3,0	7,5	4,6	0,4	3,9	0,0	3,1	-2,4	6'0	-2,2	-0.6	, -	12,9	-0,2	6,4	2.7					VARIATION (%) vs 10
Δ (T6h-T0)	1,7	5,2	-0,5	9'0	-1,5	-2,3	1,0	-1,0	3,2	-5.1	-4,3	0,4	-1,4	6,0	-3,5	2.5	. 1	0'0	1,1	-1,4	-0,5					
Δ (T1h-T0)	2,2	2,9	0,2	1.7	8,0	0,2	-2,0	-1,6	3,6	0,0	-1,4	0,5	1,4	9'0	-4,5	2,5	ŧ	0,0	-0,7	4,1-	0,4					
T48h (48 hours after product application)	42,3	33,5	37,4	30,1	30,6	32,5	38,0	37,2	34,5	33,5	31,7	35,0	36,7	34,9	36,4	36,5	ШZ	36,2	29,3	36,9	32,5	34,79	3,147	29,30	42,30	0,704
T24h (24 hours after product application)	46,5	43,0	36,8	27,6	33,5	32,4	47,4	42,5	36,7	41,3	34,8	39,8	36,1	36,7	38,4	36,1	NE	45,2	29,2	42,6	35,8	38,12	5,415	27,60	47,40	1,211
T6h (6 hours after product application)	44,0	43,0	35,8	30,5	32,5	33,1	40,9	36,9	39,5	32,3	30,5	37,1	37,1	36,7	37,1	39,2	NE	32,3	30,5	34,8	32,6	35,82	4,076	30,50	44,00	0,911
T1h (1 hour after product application)	44,5	40,7	36,5	31,6	34,8	35,6	37,9	36,3	39,9	37,4	33,4	37,2	39,9	36,4	36,1	39,2	NE	32,3	28,7	34,8	33,5	36,34	3,574	28,70	44,50	0,799
T0 - BASELINE (immediately after stripping)	42,3	37,8	36,3	29,9	34,0	35,4	39,9	37,9	36,3	37,4	34,8	36,7	38,5	35,8	40,6	36,7	[39,6]	32,3	29,4	36,2	33,1	36,07	3,252	29,40	42,30	0,727
VOL N.	1	2	3	4	5	9	7	ω	6	10	7	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	MIN	MAX	MSE

Legend: NE = not evaluated Statistical analysis: Du

Statistical analysis: Dunnett test p<0,05 T24h vs T0

Test code

E0715

### EPICUTANEOUS pH LIPOGEL SOLUZIONE P 1% (prot. 2647)

																										c	ا د
∇	(T48h-T0)	0,1	4,0	0,5	0,1	0,0	1,0	-0,1	0,3	-0,1	0,3	1.4	6,0	0,0	6,0-	0,0	-0,1	1	-0,1	0,5	0,3	0,3				T 21. (/0/ ]A	VARIATION (%) VS 10
Δ	-T0)	1,1	-0,4	6,0	0,1	0,1	1,0	0,0	-0,1	-0,2	0,2	0,4	1,3	0'0	-0,4	-0,4	0,1	1	0,1	9'0	9'0	2,5				CITAIGAV	עויי אושא
∇	(T6h-T0)	-0,4	0,0	0,0	0,1	9,0-	0,0	0,2	0,0	-0,3	-0,3	-0,1	0,2	0,1	-0,1	-0,4	0,1	_	-0,3	0,0	0,2	-0,1					
∇	(T1h-T0)	-0,4	-0,2	-0,2	0,0	0,0	-0,5	-0,2	-0,3	0,0	-0,1	0'0	0,2	0,0	-0,1	0,2	0,1	1	0'0	-0,1	0,1	0,4					
T48h (48 hours after	product application)	6,04	5,77	5,71	5,38	5,17	6,05	5,41	5,80	5,08	5,61	6,40	5,65	5,10	4,36	5,04	4,87	NE	5,08	5,56	5,40	5,21	5,435	0,471	4,36	6,40	0,105
T24h (24 hours after	product application)	7,06	5,01	5,49	5,31	5,30	6,01	5,49	5,42	4,96	5,45	5,40	6,42	5,10	4,30	4,61	5,16	NE	5,31	5,43	5,70	7,08	5,501	869'0	4,30	7,08	0,156
T6h (6 hours after		5,59	5,38	5,20	5,36	4,60	5,01	5,65	5,58	4,84	4,95	4,93	5,31	5,19	4,58	4,59	5,10	빙	4,82	5,07	5,29	4,82	5,093	0,331	4,58	5,65	0,074
T1h (1 hour after	product application)	5,54	5,20	5,00	5,27	5,11	4,53	5,29	5,28	5,14	5,22	5,00	5,32	5,10	4,54	5,17	5,14	ШN	5,12	4,95	5,21	5,34	5,124	0,242	4,53	5,54	0,054
TO - BASELINE	(Immediately after stripping)	5,94	5,40	5,20	5,24	5,16	5,04	5,50	5,55	5,14	5,29	5,04	5,11	5,10	4,65	5,00	5,02	[4,58]	5,16	5,04	5,12	4,93	5,182	0,267	4,65	5,94	090'0
	VOL N.		2	3	4	5	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	MIN	MAX	MSE

Statistical analysis: Tukey test p<0,05 at T1h vs prot. 2649

Legend: NE = not evaluated

 T1h
 T6h
 T24h
 T48h

 -1,1%
 -1,7%
 6,2%
 4,9%

### EPICUTANEOUS pH IDROGEL SOLUZIONE B (prot. 2650)

																									-	,
۵ (T48h-T0)	0,1	0,5	-0,1	6,0	-0,1	1,0	-0,1	0,3	0,2	0,0	1,2	0,7	-0,1	-0,3	-0,1	-0,1	ľ	0,2	0,3	0,1	0,1				A! (0/ ) Y	01 sy (%) NOTHWY
۵ (T24h-T0)	1,1	0,7	-0,2	0,0	-0,2	9,0	0,1	0,1	0'0	-0,1	0,1	1,2	0,0	-0,1	-0,4	0,2	•	0,2	0,5	0,1	2,0				CITAIGAN	)   VIV
۵ (T6h-T0)	-0,5	-0,2	-0,4	0'0	6'0-	0,3	0,1	-0,3	€'0-	-0,4	5'0-	-0,4	-0,1	0,0	-0,4	-0,2	-	-0,4	5'0-	-0,4	0,2					
۵ (T1h-T0)	-1,0	6'0-	-0,3	9'0-	9'0-	-1,2	-0,4	6,0-	-0,2	-0,5	-0,7	-0,4	-0,4	0,1	-0,3	-0,4	,	9'0-	-0,8	9'0-	-0,1			4200-00	W. C.	
T48h (48 hours after product application)	5,97	5,86	5,04	5,32	5,00	6,15	5,31	5,91	5,07	5,29	6,10	5,70	5,03	4,40	5,08	4,86	NE	5,33	5,52	5,37	5,05	5,368	0,460	4,40	6,15	0,103
T24h (24 hours after product application)	96'9	6,12	4,89	5,00	4,91	5,85	5,47	5,68	4,85	5,16	5,02	6,23	5,10	4,61	4,77	5,13	ШN	5,32	5,72	5,37	6,97	5,457	0,680	4,61	6,97	0,152
T6h (6 hours after product application)	5,28	5,20	4,72	5,09	4,23	5,51	5,48	5,36	4,61	4,89	4,43	4,62	5,02	4,72	4,76	4,75	핏	4,68	4,67	4,94	5,10	4,903	0,347	4,23	5,51	0,078
T1h (1 hour after product application)	4,83	4,50	4,80	4,48	4,48	4,02	4,95	4,69	4,66	4,76	4,27	4,65	4,71	4,78	4,87	4,57	Ш	4,50	4,36	4,75	4,80	4,622	0,227	4,02	4,95	0,051
T0 - BASELINE (immediately after stripping)	5,82	5,40	5,10	5,04	5,11	5,20	5,39	5,62	4,87	5,29	4,94	5,00	5,10	4,71	5,20	4,94	[4,58]	5,11	5,18	5,31	4,94	5,164	0,260	4,71	5,82	0,058
VOL N.	1	2	က	4	5	9	7	∞	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	NIE	MAX	MSE

Legend: NE = not evaluated

Statistical analysis: Dunnett test p<0,05 T1h vs T0; Tukey test p<0,05 at T1h vs prot. 2647 and 2648

•	T48h	4,0%
	T24h	5,7%
	T6h	-5,1%
	Tth	-10,5%

T48h

T24h

T6h

**11**h

4,9%

6,0%

-0,2%

-3,2%

### INSTRUMENTAL EVALUATION

### LIPOGEL SOLUZIONE CONTROLLO 1% (prot. 2648) **EPICUTANEOUS pH**

< 1	(T48h-T0)	-0,1	0,5	0,3	0,0	-0,1	0,7	-0,2	0,1	0,1	0,0	1,3	9,0	6,0	0,1	-0,2	9,0	1	0,0	6,0	0,1	0,4				T 2:: 1/0/ IV	01 ev (%) NOLLAINAV
V	(T24h-T0)	9,0	-0,1	1,4	0,1	-0,3	2,0	0,1	0,3	0,1	0,1	0,2	2,0	0,4	-0,3	9,0-	8,0	•	0,2	6,0	6,0	1,3				CITAIGAY	איאאי
4	(T6h-T0)	0,2	0,1	-0,1	0,4	-0,5	-0,2	0,2	0,1	-0,3	-0,4	-0,1	6,0	0,1	-0,1	9'0-	0,3	-	-0,2	0,0	2'0	-0,2					
∇	(T1h-T0)	0,1	-0,2	-0,1	-0,1	-0,5	6,0-	0,0	-0,2	-0,4	9'0-	-0,2	0,2	0,0	-0,1	-0,2	0,0	ı	0,1	-0,1	-0,1	0,1					
T48h (48 hours after	product application)	5,90	5,83	5,34	5,38	5,19	5,75	5,35	5,65	5,20	5,59	6,25	5,59	5,23	4,67	5,13	5,51	NE	5,16	5,49	5,41	5,40	5,451	0,338	4,67	6,25	0,075
T24h (24 hours after	product application)	6,61	5,24	6,40	5,53	5,03	5,70	5,61	5,84	5,25	5,65	5,16	5,69	5,30	4,33	4,68	5,76	NE	5,28	5,33	5,61	6,21	5,511	0,537	4,33	6,61	0,120
T6h (6 hours after	product application)	6,17	5,44	4,90	5,80	4,77	4,81	5,74	5,68	4,88	5,12	4,91	5,24	5,10	4,50	4,70	5,29	NE	4,96	5,01	5,92	4,78	5,186	0,461	4,50	6,17	0,103
T1h (1 hour after	product application)	6,12	5,10	4,90	5,26	4,80	4,10	5,50	5,32	4,79	4,96	4,83	5,13	4,98	4,50	5,09	4,93	NE	5,20	4,91	5,12	5,10	5,032	0,394	4,10	6,12	0,088
T0 - BASELINE	(immediately after stripping)	6,01	5,30	5,00	5,40	5,29	5,03	5,52	5,54	5,14	95'5	5,00	4,97	4,95	4,61	5,30	4,96	[4,63]	5,12	5,01	5,27	4,96	5,197	608'0	4,61	6,01	690'0
100	VOL N.	1	2	3	4	5	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST. DEV.	MIN	MAX	MSE

Legend: NE = not evaluated

Statistical analysis: Dunnett test p<0,05 T24h and T48h vs T0

8,3%

4,3%

-4,6%

-10,7%

T48h

T24h

T6h

T1h

### INSTRUMENTAL EVALUATION

### EPICUTANEOUS pH IDROGEL SOLUZIONE CONTROLLO (prot. 2649)

																											_
	(T48h-T0)	0,0	0,5	0,4	-0,1	0,0	0,8	-0,1	0,0	0,0	-0,2	6,0	0,7	0,7	3,5	0,4	9.0	1	0,4	0,1	0'0	0,1				1	) (%) vs
	(T24h-T0)	1.0	-0,2	0,1	-0,2	-0,3	0,4	0,1	0,3	0,2	0,0	90	1,2	7,0	0,2	-0,3	0,7	,	0,5	0,0	0,2	0,4	the state of the s				VAKIATION (%) vs 10
	(T6h-T0)	-0,7	-0,1	-0,4	0,3	-0,5	9,0-	-0,2	-0,2	9,0-	0,4	9,0-	0,2	0,2	0,3	-0,2	0,1	1	-0,5	-0,7	-0,4	-0,7					
4	(T1h-T0)	-1,0	6,0-	-0,5	-0,5	6,0-	-1,0	9,0-	-1,1-	-0,5	9'0-	8,0	-0,1	-0,1	0,2	-0,1	-0,5	1	-0,4	8,0-	-0,7	-0,4					
T48h (48 hours after	product application)	6,08	5,86	5,40	4,96	5,44	90'9	5,41	5,70	5,16	5,35	6,12	5,76	5,43	7,98	5,30	5,74	IJN.	5,61	5,43	5,33	5,58	5,685	0,622	4,96	7,98	0,139
T24h (24 hours after	product application)	7,03	5,23	5,06	4,85	5,15	5,65	5,63	5,92	5,36	5,60	4,64	6,28	5,49	4,72	4,67	5,86	NE	5,67	5,31	5,53	5,82	5,474	0,577	4,64	7,03	0,129
T6h (6 hours after	in the same of the	5,35	5,33	4,61	5,36	4,96	4,68	5,38	5,43	4,58	5,97	4,58	5,21	4,93	4,79	4,71	5,21	NE	4,71	4,64	4,94	4,79	5,008	0,378	4,58	5,97	0,085
T1h (1 hour after	product application)	5,05	4,50	4,50	4,56	4,51	4,25	4,95	4,51	4,65	4,98	4,47	4,94	4,61	4,70	4,87	4,65	N N	4,82	4,51	4,66	5,02	4,686	0,222	4,25	5,05	0,050
To - BASELINE	(minediately after stripping)	6,03	5,40	5,00	5,02	5,41	5,25	5,53	5,65	5,19	5,57	5,22	5,06	4,75	4,50	4,95	5,15	[5,11]	5,20	5,31	5,32	5,44	5,248	0,333	4,50	6,03	0,075
5	, N	_	2	ဂ	4	5	9	7	80	6	10	_	12	13	14	15	16	17	18	9	20	21	MEAN	ST. DEV.	MIN	MAX	MSE

Legend: NE = not evaluated

Statistical analysis: Dunnett test p<0,05 T1h vs T0; Tukey test p<0,05 at T1h vs prot. 2648

-18,8%

%2'6-

-3,9%

-16,8%

Statistical analysis: Dunnett test p<0,05 T1h and T48h vs T0

Legend: NE = not evaluated

Test code E0715

### INSTRUMENTAL EVALUATION

DermIng S.r.l., Clinical Research and Bioengineering Institute

## **TEWL (Transepidermal Water Loss)**

1	7647
•	
	E F 1%
	<b>ヽ</b> !
•	_

																													Ľ.		T48h
	۵	(T48h-T0)		mean	-5,1	-4,7	-0,5	-6,2	-1,8	-1,3	-30,1	-7,2	-1,0	-2,2	-1,6	0,9	-8,3	4,2	-8,3	-1,4	1	-1,9	-0,3	-2,7	4,3				VS BASE!		T24h
	۵	(T24h-T0) (T48h-T0)		mean	3,6	-2,5	-0,2	-1,1	1,6	-1,0	-20,4	-4,1	0,2	-2,2	2,3	-0,1	-8,9	1,1	-4,2	-3,4	_	1,0	3,4	-3,3	-0,6				% VARIATION VS BASFI INF		Т6һ
	۵	(T6h-T0)		mean value	1,2	-4,4	-0,7	9,0	3,1	1,0	-10,8	-0,1	-0,4	-2,2	0,6	0,1	-2,7	4,6	-4,8	5,4		9'0	-1,9	-2,2	-2,5				1 %	2	T1h
	۵	(T1h-T0)		mean value	0'9-	4,4	-1,3	-2,0	-2,4	-1,5	-15,3	-5,3	-2,6	-4,2	2'0-	2'0-	9'8-	1,7	-8,1	-2,7	-	0,2	8,0-	-2,2	-0,5						
T48h	(48 hours after	product	anony	st.dev	0,41	0,29	0,37	0,17	0,21	90'0	0,37	0,34	0,19	0,26	0,12	20,0	0,31	0,19	96,0	90'0	JN	0,17	0,43	0,29	0,63	0,265	0,145	0,032	0,05	0,63	
<u>T</u>	(48 hou	product	appiic	mean value	19,9	15,6	17,2	8,8	18,4	15,8	12,7	16,1	17,5	12,9	14,9	18,2	10,9	21,5	10,9	19,4	Ä	13,2	19,6	15,9	24,4	16,19	3,892	0,870	ထ်	24,4	
T24h	rs after	luct	ations	st.dev	70,0	0,33	0,26	90,0	0,16	0,19	0,33	06'0	0,10	0,40	0,13	0,51	0,48	0,26	0,14	0,26	ΞN	0,25	0,20	0,15	0,43	0,282	0,195	0,044	0,07	06'0	
T2	(24 hours after	product	appilic	mean	28,6	17,8	17,5	13,9	21,8	16,1	22,4	19,2	18,7	12,9	18,8	17,2	10,3	18,4	15,0	17,4	뷜	16,1	23,3	15,3	19,5	18,01	4,014	0,898	10,3	28,6	
ų.	s after	luct	ation,	st.dev	0,39	0,19	0,32	0,34	0,15	0,17	0,30	0,24	0,14	0,17	90,0	0,23	0,35	0,34	0,23	0,18	ΨZ	0,20	0,42	69'0	0,13	0,263	0,138	0,031	0,08	69'0	
T6h	(6 hours after	product	applic	mean	26,2	15,9	17,0	15,6	23,3	18,1	32,0	23,2	18,1	12,9	17,1	17,4	16,5	21,9	14,4	26,2	J N	15,7	18,0	16,4	17,6	19,18	4,784	1,070	12,9	32,0	
	r after	fuct	allolly	st.dev	0,11	0,41	0,19	0,26	0,28	0,25	0,35	0,50	0,68	0,47	0,28	0,55	0,11	0,33	0,59	0,11	NE NE	0,13	0,28	0,24	0,13	0,313	0,172	0,038	0,11	0,68	
T1h	(1 hour after	product	applications	mean	19,0	15,9	16,4	13,1	17,8	15,6	27,5	18,0	15,9	10,9	15,8	16,6	10,6	19,0	11,1	18,1	N N	15,3	19,1	16,4	19,9	16,60	3,761	0,841	10,6	27,5	
	SELINE	tely after oing)		st.dev	0,17	0,16	0,30	0,17	0,19	0,10	0,25	0,25	0,22	0,54	0,12	0,16	0,34	0,48	0,43	0,41	[0,54]	0,26	0,13	0,35	0,28	0,266	0,125	0,028	0,10	0,54	
	TO - BASELINE	(immediately after stripping)		mean	25,0	20,3	17,7	15,0	20,2	17,1	42,8	23,3	18,5	15,1	16,5	17.3	19,2	17,3	19,2	20,8	[4,8]	15,1	19,9	18,6	20,1	19,95	5,961	1,333	15,0	42,8	
		VOL N.			7	2	3	4	5	9	7	80	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST.DEV.	MSE	Z	MAX	

-23,7%

-17,4%

-10,1%

-17,5%

DermIng S.r.l., Clinical Research and Bioengineering Institute

### INSTRUMENTAL EVALUATION

## TEWL (Transepidermal Water Loss)

## IDROGEL SOLUZIONE B (prot. 2650)

																														Ш		T48h
	◁	(T48h-T0)		mean	-16.5	9 9	0,0	2,3	-11,7	-2,0	-0,9	-14,9	-4,0	-2,4	-0,4	-2,5	0,8	-13,7	0,1	-18,4	1,7	Ī	8,5,	6'0-	-3,8	-0,4				VS BASELL		T24h
e de la companya de l	4	(T24h-T0) (T48h-T0)		mean	-9.4	0 5	0,4-	9,0	-7,8	-0,2	0,0	-6,4	-1,5	-2,5	0,0	-0,1	1,6	-19,9	-0,2	-18,1	0,5	j	-1,0	0,1	-2,7	-0,5				" VARIATION VS BASELINE		T6h
	٥	(T6h-T0)		mean	value -6.6	CU	5,0-	-1,4	-4,8	-1,6	0,3	-2,3	6'9	5,3	-1,3	5'0	0,0	-13,1	2,2	-17,2	0,8	-	-1,1	-0,8	-2,0	-0,3				\ %		7
	٥	(T1h-T0)		mean	value -14.4		-0,4	9,0-	-8,7	-1,1	-1,6	5,1	-2,3	0,1	-2,9	-1,9	1,8	-17,1	1,3	-12,3	9'0-	_	-7,1	-2,1	-2,0	0,2		A lan-income	0.00			•
T48h	(48 hours after	product	,	st.dev	0.89	1000	co'n	0,04	0,23	60'0	0,19	0,15	0,38	0,28	0,16	89'0	0,26	0,15	0,16	0,50	0,10	NE	0,13	0,08	0,16	0,33	0,281	0,230	0,051	0,04	0,89	
7 <u>L</u>	(48 hou	pro	222	mean	value 17.4		13,0	19,8	4,7	14,6	16,9	15,9	17,5	14,3	21,1	13,2	18,4	15,8	17,4	14,5	18,7	빙	12,0	17,1	14,4	19,4	15,81	3,574	0,799	4,7	21,1	
T24h	(24 hours after	product	ation,	st.dev	0.35	50.50	0,23	0,21	0,42	0,05	0,10	69'0	0,25	0,44	0,16	0,10	0,14	08'0	0,43	0,65	0,22	빌	0,18	0,19	1,03	0,26	0,319	0,240	0,054	0,05	1,03	
12	(24 hou	product	2	mean	value 24.5	7	15,0	18,1	8,6	16,4	17,8	24,4	20,0	14,2	21,5	15,6	19,2	9'6	17,1	14,8	17,5	Ŋ	14,8	18,1	15,5	19,3	17,10	4,006	0,896	8,6	24,5	
	6 hours after	luct	45011	st.dev	0.38	2	0,41	0,24	0,05	0,29	0,14	0,27	0,45	0,34	0,25	0,16	69'0	0,74	0,37	0,12	0,30	NE	0,22	0,22	0,15	0,19	0,299	0,176	0,039	0,05	0,74	
T6h	(6 hour	product	applic	mean	value 273	2,7	14,3	16,1	11,6	15,0	18,1	28,5	28,4	22,0	20,2	16,2	17,6	16,4	19,5	15,7	17,8	NE	14,7	17,2	16,2	19,5	18,62	4,679	1,046	11,6	28,5	
	rafter	luct ation)	ations	st.dev	0.21	100	0,21	0,17	0,15	0,14	0,12	0,32	0,20	0,13	0,23	0,39	0,41	0,30	0,37	0,14	0,62	NE	0,34	0,31	0,20	0,30	0,263	0,125	0,028	0,12	0,62	
<b>4</b> L	(1 hour after	product	2	mean	Value 19 5	2,0	13,2	16,9	7.7	15,5	16,2	35,9	19,2	16,8	18,6	13,8	19,4	12,4	18,6	20,6	16,4	NE	8,7	15,9	16,2	20,0	17,08	5,654	1,264	2,7	35,9	
	SELINE	tely after ying)		st.dev	O A O		0,15	0,18	0,16	70,0	0,25	0,25	0,19	0,14	69'0	0,25	0,19	0,48	0,88	0,28	0,29	[0,19]	0,38	0,22	0,17	0,22	0,292	0,196	0,044	0,07	0,88	
	10 - BASELINE	(immediately after stripping)		mean	value ૧૩ ૦	0,0	19,6	17,5	16,4	16,6	17,8	30,8	21,5	16,7	21,5	15,7	17,6	29,5	17,3	32,9	17,0	[3,2]	15,8	18,0	18,2	19,8	20,71	5,952	1,331	15,7	33,9	
in the state of th		YOL N.	audi	And the second the	-	-	2	ന	4	5	9		8	0	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST.DEV.	MSE	2	MAX	ND COLOR OF THE CO

Legend: NE = not evaluated

Statistical analysis: Dunnett test p<0,05 T1h and T48h vs T0

-23,1%

-14,2%

-11,1%

-19,4%

# DermIng S.r.l., Clinical Research and Bioengineering Institute

### INSTRUMENTAL EVALUATION

## TEWL (Transepidermal Water Loss)

# LIPOGEL SOLUZIONE CONTROLLO 1% (prot. 2648)

																													NE NE		T48h
	۵	(T48h-T0)		mean -	-14 1	86-	9.0	-10.1	0,1	-3,2	-21,9	-7,0	0,0	-10,1	-2,8	0,2	-3,8	1,2	-3,8	-0,3	-	8,4	-1,6	-2,9	-2,7	G.			vs BASELI		T24h
e Bossourios	۵	(T24h-T0)		mean	value _9.4	-6.0	-0.6	-1,4	8,3	-2,5	-13,2	-5,4	6,0-	-7,5	-1,4	-0,4	-3,2	-0,8	-3,4	4,0	1	-2,6	-0,1	-1,9	-3,2				% VARIATION vs BASELINE		T6h
	٥	(T6h-T0)		mean	-10.7	-11.4	-12	1,9	3,5	-1,2	-10,0	-3,6	3,9	4,4	0,3	-0,3	-1,4	6,0	-2,8	-1,2	ŝ	-2,5	-2,4	1,1-	-2,2				\%		T1h
	۵	(T1h-T0)		mean	value -9.2	-11.1	-1.7	-1,5	1,5	-3,0	-14,5	-5,2	9,0-	-7,2	8,0	-1,9	-8 <u>,</u> 4	-2,1	-4,4	-0,7	-	-2,9	7'0-	4,3	-4,4						
	T48h (48 hours after	product application)	,	st.dev	1 92	0.11	0.08	0,14	0,10	0,22	0,23	0,15	0,63	0,22	0,12	0,29	0,43	0,30	0,21	0,49	JN.	0,68	0,55	0,43	0,55	0,393	0,406	0,091	0,08	1,92	
	14 (48 hou	pro	J.J.	mean	value 18.1	9.2	16.8	11,0	18,2	16,3	16,0	11,9	17,6	15,8	14,7	17,8	17,6	18,8	12,8	20,1	빙	13,6	16,6	19,1	20,6	16,13	3,074	0,687	9,2	20'p	
	i 24h (24 hours after	product application)	,	st.dev	0.20	0.18	0.23	0,10	0,44	0,19	0,27	0,25	0,37	0,50	0,26	0,75	0,36	0,33	0,45	0,30	빙	0,24	0,68	0,21	0,37	0,334	0,165	0,037	0,10	0,75	
	12 (24 hou	pro		mean	22.8	13.0	15.6	19,7	26,4	17,0	24,7	13,5	16,7	18,4	16,1	17,2	18,2	16,8	13,2	16,4	븯	15,8	18,1	20,1	20,1	17,99	3,556	0,795	13,0	20,4	
	sh rs after	product	,	st.dev	0.33	0.14	0.10	0,21	0,43	0,16	0,21	0,37	0,34	0,49	0,17	0,45	0,39	0,12	0,23	0,26	믣	0,10	0,48	0,49	0,39	0,293	0,138	0,031	0,10	0,48	
Management of the party of the	l 6n (6 hours after	product		mean	71.5	7.6	15.0	23,0	21,6	18,3	27,9	15,3	21,5	21,5	17,8	17,3	20'0	6'21	13,8	19,2	ΞN	15,9	15,8	20,9	21,1	18,65	4,229	0,946	7,6	6,12	
	In r after	luct ation)	,	st.dev	0.40	0.24	0.38	0,23	0,14	0,20	0,19	0,21	0,12	0,21	11'0	0,52	1,31	06,0	0,10	0,13	∃N	0,58	0,04	0,73	0,79	0,350	0,308	690'0	0,04	1,31	
	11h (1 hour after	product application)		mean	23.0	7.9	14.5	19,6	19,6	16,5	23,4	13,7	17,0	18,7	18,3	15,7	13,0	15,5	12,2	19,7	NE	15,5	17,5	17,7	18,9	16,90	3,641	0,814	7,9	23,4	
	SELINE	tery after oing)		st.dev	0.33	0,27	0,19	06'0	0,07	0,12	66,0	0,33	0,21	0,45	20'0	0,15	0,21	0,12	0,20	0,42	[0,26]	0,19	0,13	0,35	1,22	0,316	0,283	0,063	0,07	1,44	
	TO - BASELINE	(IIIIIIIIediately aiter stripping)	4. 4. 4.	mean	32.2	19,0	16,2	21,1	18,1	19,5	37,9	18,9	17,6	25,9	17,5	17,6	21,4	17,6	16,6	20,4	[5,5]	18,4	18,2	22,0	23,3	20,97	5,452	1,219	16,2	37,3	
ľ		VOL N.			_	2	3	4	5	ၑ	7	80	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST.DEV.	MSE	NIN S	WAA	

Legend: NE = not evaluated

Statistical analysis: Dunnett test p<0,05 T1h, T24h and T48h vs T0

**T48h**-22,4%

-15,5%

~6,7%

-15,6%

### INSTRUMENTAL EVALUATION

### TEWL (Transepidermal Water Loss)

# IDROGEL SOLUZIONE CONTROLLO (prot. 2649)

																			workin/Office		nowwe w	Name of the last		vomente von	onenha mile	and the second				Z Z	È
	◁	(T48h-T0)		mean	value	-11,8	-6,4	-0,1	-3,4	-14,8	-2,0	-18,7	-15,1	-1,2	-7,5	-4,5	-1,2	-5,5	9,0	1,1	3,9	ſ	-3,3	-1,3	-3,0	-3,3				vs BASEL	T24h
	٥	(T24h-T0) (T48h-T0)		mean	value	-4,2	6,7-	0,0	-1,7	-10,2	0,0	-15,1	0,6-	-2,0	-2,5	4,6	-2,1	-3,5	-1,3	2,7	1,3	1	-2,5	-0,5	-2,0	-2,4				% VARIATION vs BASELINE	T6h
	٥	(T6h-T0)		mean	value	-4,6	-3,4	-0,2	1,0	-2,8	1,0	-10,4	-5,9	3,8	-11,2	0,2	5,6	-0,2	-1,3	1,5	3,2	1	-4,6	1,6	-0,4	-1,9				%	T1h
	٥	(T1h-T0)		mean	value	-6,4	-4,1	-2,0	8'0-	ဇ'ဇ-	-1,5	6,8-	-8,2	-1,1	-6,4	-2,3	1,0	0.Θ	-1,0	-0,5	3,3	1	0'2-	-1,3	-3,3	-8,0					=
T48h	48 hours after	product	application)	st dev		0,37	0,27	0,28	80'0	0,56	0,25	0,10	0,10	0,82	0,26	0,33	0,69	0,42	0,13	0,04	0,31	NE	0,15	0,94	0,85	0,27	0,361	0,272	0,061	0,04 0,94	
7	(48 hou	pro	applic	mean	value	19,9	13,3	19,2	12,3	15,7	17,2	15,9	17,0	14,7	14,2	16,3	14,3	15,9	18,0	21,9	20,9	N N	14,4	15,6	19,3	21,3	16,87	2,776	0,621	12,3 21,9	The state of the s
T24h	(24 hours after	product	application)	st day	35.00	0,39	0,49	0,20	0,17	0,16	0,58	0,94	06,0	0,24	0,26	0,43	0,38	0,45	1,71	0,10	0,08	NE	0,36	0,23	0,35	0,24	0,403	0,363	0,081	0,08 1,71	The state of the s
ï	(24 hou	D.G.	applic	mean	value	27,5	11,8	19,3	14,0	20,3	19,2	19,5	23,1	13,9	19,2	16,2	13,4	17,9	16,1	23,5	18,3	NE	15,2	16,7	20,3	22,2	18,38	3,889	0,870	11,8 27,5	A CONTRACTOR OF THE CONTRACTOR
T6h	(6 hours after	product	application)	of dov	36.454	0,31	0,19	0,14	0,10	0,14	0,10	0,43	0,26	0,24	0,39	0,17	0,28	0,31	0,90	0,19	0,20	NE	0,22	0,18	0,52	0,12	0,270	0,186	0,042	0,10 0,90	
Ĭ	nou 9)	pro	applic	mean	value	27,1	16,3	19,1	16,7	27,7	20,2	24,2	26,2	19,7	10,5	21,0	21,1	21,2	16,1	22,3	20,2	JN N	13,1	18,5	21,9	22,7	20,29	4,382	0,980	10,5 27,7	SMAR COLUMN TO THE STATE OF THE
T1h	(1 hour after	product	application)	, do	St.dev	0,40	0,30	0,10	0,19	0,20	0,10	0,19	0,22	0,05	0,19	0,17	0,19	0,20	0,39	0,37	0,15	IJN.	0,15	06'0	1,71	0,52	0,335	0,375	0,084	0,05	
<b>j</b>	(1 hot	pro	applic	mean	value	25,3	15,6	17,3	14,9	27,2	17,7	25,7	23,9	14,8	15,3	18,5	16,5	15,4	16,4	20,3	20,3	ШN	10,7	15,6	19,0	16,6	18,35	4,276	0,956	10,7 27,2	
		(immediately arter stripping)	(Bind)	, c	). D	0,27	0,17	09'0	0,18	0,19	0,22	0,32	0,12	0,10	0,39	0,18	0,22	0,32	0,11	0,10	29'0	[0,25]	0,13	0,94	0,11	0,17	0,276	0,222	0,050	0,10 0,94	
- C	ī :	(Immedi:	2 5 0	mean	value	31,7	19,7	19,3	15,7	30,5	19,2	34,6	32,1	15,9	21,7	20,8	15,5	21,4	17,4	20,8	17,0	[6,4]	17,7	16,9	22,3	24,6	21,74	5,921	1,324	15,5 34,6	
		5	֭֭֭֓֞֝֞֝֟֝֟֝֟֝֟֝			_	2	3	4	5	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20	21	MEAN	ST.DEV.	MSE	MIN MAX	

Statistical analysis: Dunnett test p<0,05 T1h, T24h and T48h vs T0

Legend: NE = not evaluated

### PROFILOMETRY (Surface microrelief) Sa (arithmetic roughness)

### LIPOGEL SOLUZIONE P 1% (prot. 2647)

VOL N.	T0 - BASELINE (immediately after stripping)	T48h (48 hours after product application)	Δ (T48h-T0)
1	26	30	4
2	17	17	0
3	25	24	-1
4	21	26	5
5	16	19	3
6	21	21	0
7	18	22	4
8	21	24	3
9	31	34	3
10	15	18	3
11	23	24	1
12	15	15	0
13	19	18	-1
14	17	15	-2
15	15	12	-3
16	19	23	4
17	[27]	NE	-
18	24	21	-3
19	17	15	-2
20	25	23	-2
21	17	20	3
MEAN	20,1	21,1	
ST.DEV	4,400	5,326	
MIN	15	12	
MAX	31	34	
MSE	0,984	1,191	

LEGEND: NE= not evaluated

% VARIATION vs BASELINE	
5,0%	

### PROFILOMETRY (Surface microrelief) Sa (arithmetic roughness)

### **IDROGEL SOLUZIONE B (prot. 2650)**

VOL N.	T0 - BASELINE (immediately after stripping)	T48h (48 hours after product application)	Δ (T48h-T0)
1	24	27	3
2	15	19	4
3	31	31	0
4	20	20	0
5	15	18	3
6	22	22	0
7	20	20	0
8	18	20	2
9	35	34	-1
10	14	18	4
11	20	22	2
12	15	17	
13	18	17	-1
14	17	15	-2
15	11	11	0
16	22	28	6
17	[26]	NE	-
18	26	29	3
19	15	16	1
20	24	24	0
21	17	20	3
MEAN	20,0	21,4	
ST.DEV	5,916	5,826	
MIN	11	11	
MAX	35	34	
MSE	1,323	1,303	

LEGEND: NE= not evaluated

% VARIATION vs	BASELINE
7,0%	

Statistical analysis: Student t test p<0,01 vs T0

### PROFILOMETRY (Surface microrelief) Sa (arithmetic roughness)

### **LIPOGEL SOLUZIONE CONTROLLO 1% (prot. 2648)**

VOL N.	T0 - BASELINE (immediately after stripping)	T48h (48 hours after product application)	Δ (T48h-T0)
1	22	23	1
2	16	19	3
3	20	24	4
4	26	22	-4
5	17	16	-1
6	20	21	1
7	17	20	3
8	21	20	-1
9	31	34	3
10	16	20	4
11	19	20	1
12	14	16	2
13	16	14	-2
14	17	14	-3
15	14	15	1
16	22	25	3
17	[22]	NE	-
18	22	22	0
19	19	16	-3
20	21	22	1
21	16	23	7
MEAN	19,3	20,3	
ST.DEV	4,143	4,658	
MIN	14	14	
MAX	31	34	
MSE	0,927	1,042	

LEGEND: NE= not evaluated

% VARIATION vs BASELINE	
5,2%	

### PROFILOMETRY (Surface microrelief) Sa (arithmetic roughness)

### **IDROGEL SOLUZIONE CONTROLLO (prot. 2649)**

VOL N.	T0 - BASELINE (immediately after stripping)	T48h (48 hours after product application)	Δ (T48h-T0)
1	24	25	1
2	14	20	6
3	30	35	5
4	22	20	-2
5	16	15	-1
6	23	24	1
7	16	18	2
8	18	16	-2
9	34	30	-4
10	18	21	3
11	17	22	5
12	15	15	0
13	16	15	-1
14	16	15	-1
15	20	12	-8
16	32	25	-7
17	[28]	NE	-
18	21	24	3
19	14	14	0
20	21	18	-3
21	16	22	6
MEAN	20,2	20,3	
ST.DEV	5,914	5,796	
MIN	14	12	
MAX	34	35	
MSE	1,322	1,296	

LEGEND: NE= not evaluated

% VARIATION vs BASELINE			
	0,5%	_	

### STATISTICAL ANALYSIS SUMMARY TABLES

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

# STATISTICAL ANALYSIS - SUMMARY TABLE CLINICAL ASSESSMENT

ERYTHEMA VISUAL SCORE comparison vs T0			nett test
companson vs 10	p-value	Times	Significance
	1000 yanada antari ami'a antari a	T0-T1h	*p<0,05
Lipogel	0.000 S	T0-T6h	NS
soluzione P 1%	0.000 5	T0-T24h	*p<0,05
		T0-T48h	*p<0,05
		T0-T1h	*p<0,05
ldrogel	0.000 S	T0-T6h	*p<0,05
soluzione B	0.000 3	T0-T24h	*p<0,05
		T0-T48h	*p<0,05
		T0-T1h	*p<0,05
Lipogel	0.000 S	T0-T6h	NS
soluzione controllo 1%	0.000 S	T0-T24h	*p<0,05
34 VICEORIES		T0-T48h	*p<0,05
		T0-T1h	*p<0,05
ldrogel	0.000 6	T0-T6h	NS
soluzione controllo	0.000 S	T0-T24h	*p<0,05
		T0-T48h	*p<0,05

	Kruskal Wallis test		
	p-value	Times	Significance
	0,492	TO	NS
ERYTHEMA VISUAL SCORE	1,000	T1h	NS
products comparison	1,000	T6h	NS
time by time	1,000	T24h	NS
	1,000	T48h	NS

Legend: S = statistically significative

# STATISTICAL ANALYSIS - SUMMARY TABLE INSTRUMENTAL EVALUATION (1)

OPTICAL DENSITOMETRY comparison vs T0	ANOVA test	Dunnett test	
gompanion to 10	p-value	Times	Significance
		T0-T1h	*p<0,05
Lipogel	0.000 S	T0-T6h	*p<0,05
soluzione P 1%	0.000 3	T0-T24h	*p<0,05
		T0-T48h	*p<0,05
		T0-T1h	*p<0,05
Idrogel	0.000 S	T0-T6h	*p<0,05
soluzione B		T0-T24h	*p<0,05
		T0-T48h	*p<0,05
	3390-2011	T0-T1h	*p<0,05
Lipogel	0.000 6	T0-T6h	*p<0,05
soluzione controllo 1%	0.000 S	T0-T24h	*p<0,05
		T0-T48h	*p<0,05
	) Demot V ликон также Ангерия по постоя на постоя на постоя и выболу (постоя на предоставления и выболяем и вы	T0-T1h	*p<0,05
ldrogel	0.000 S	T0-T6h	*p<0,05
soluzione controllo		T0-T24h	*p<0,05
		T0-T48h	*p<0,05

	ANOVA test		
	p-value	Times	Significance
	0,861	T0	NS
OPTICAL DENSITOMETRY	0,909	T1h	NS
products comparison	0,600	T6h	NS
time by time	0,848	T24h	NS
	0,807	T48h	NS

Legend: S = statistically significative

### STATISTICAL ANALYSIS - SUMMARY TABLE

### **INSTRUMENTAL EVALUATION (2)**

OPTICAL COLORIMETRY a* parameter comparison vs T0	ANOVA test	Duni	nett test
	p-value	Times	Significance
		T0-T1h	*p<0,05
Lipogel	0.000 6	T0-T6h	*p<0,05
soluzione P 1%	0.000 S	T0-T24h	*p<0,05
		T0-T48h	*p<0,05
and the second s	0.000 S	T0-T1h	*p<0,05
ldrogel		T0-T6h	*p<0,05
soluzione B		T0-T24h	*p<0,05
		T0-T48h	*p<0,05
		T0-T1h	*p<0,05
Lipogel	0.000.0	T0-T6h	*p<0,05
soluzione controllo 1%	0.000 S	T0-T24h	*p<0,05
		T0-T48h	*p<0,05
		T0-T1h	*p<0,05
ldrogel	0.000 C	T0-T6h	*p<0,05
soluzione controllo	0.000 S	T0-T24h	*p<0,05
		T0-T48h	*p<0,05

National Action Control of Contro	ANOVA test		
	p-value	Times	Significance
OPTICAL COLORIMETRY  a* parameter  products comparison	0,892	ТО	NS
	0,986	T1h	NS
	0,953	T6h	NS
	0,963	T24h	NS
time by time	0,924	T48h	NS

Legend: S = statistically significative

# STATISTICAL ANALYSIS - SUMMARY TABLE INSTRUMENTAL EVALUATION (3)

SKIN ELECTRICAL	ANOVA test	Duni	nett test
CAPACITANCE		Equ 1	0:::6
comparison vs T0	p-value	Times	Significance
	, vi	T0-T1h	NS
		T0-T6h	*p<0,05
		T0-T24h	NS
		T0-T48h	NS
Lipogel	0.000 S	T1h-T6h	NS
soluzione P 1%	0.000 S	T1h-T24h	*p<0,05
		T1h-T48h	*p<0,05
		T6h-T24h	*p<0,05
		T6h-T48h	*p<0,05
		T24h-T48h	NS
		T0-T1h	*p<0,05
		T0-T6h	NS
		T0-T24h	NS
		T0-T48h	*p<0,05
ldrogel	0.000 S	T1h-T6h	NS
soluzione B	0,000 5	T1h-T24h	*p<0,05
		T1h-T48h	*p<0,05
		T6h-T24h	*p<0,05
		T6h-T48h	*p<0,05
		T24h-T48h	NS
		T0-T1h	NS
		T0-T6h	NS
		T0-T24h	NS
		T0-T48h	*p<0,05
Lipogel	0.000 S	T1h-T6h	NS
soluzione controllo 1%	0.000 S	T1h-T24h	NS
	:	T1h-T48h	*p<0,05
		T6h-T24h	*p<0,05
		T6h-T48h	*p<0,05
######################################		T24h-T48h	*p<0,05
	A Males and the second description of the se	T0-T1h	*p<0,05
	B	T0-T6h	*p<0,05
		T0-T24h	NS
	]	T0-T48h	*p<0,05
ldrogel	0.000 8	T1h-T6h	NS
soluzione controllo	0.000 S	T1h-T24h	*p<0,05
		T1h-T48h	*p<0,05
		T6h-T24h	*p<0,05
		T6h-T48h	*p<0,05
		T24h-T48h	NS

	Anova test		
F	p-value	Times	Significance
	0,947	ТО	NS
SKIN ELECTRICAL CAPACITANCE products comparison time by time	0,188	T1h	NS
	0,287	T6h	NS
	0,654	T24h	NS
	0,902	T48h	NS

Legend:

S = statistically significative

NS = statistically not significative

## STATISTICAL ANALYSIS - SUMMARY TABLE **INSTRUMENTAL EVALUATION (4)**

DEEP SKIN HYDRATION	Friedman/Anova test	Duni	nett test
comparison vs T0	p-value	Times	Significance
		T0-T1h	na
Lipogel	0.736 NS	T0-T6h	na
soluzione P 1%	U./30 NS	T0-T24h	na
		T0-T48h	na
	0.013 S	T0-T1h	NS
ldrogel		T0-T6h	NS
soluzione B		T0-T24h	NS
		T0-T48h	*p<0,05
		T0-T1h	NS
Lipogel	0.021 S	T0-T6h	NS
soluzione controllo 1%	lo 1% 0.031 S	T0-T24h	NS
		T0-T48h	NS
		T0-T1h	NS
ldrogel	0.000 S	T0-T6h	NS
soluzione controllo		T0-T24h	*p<0,05
		T0-T48h	NS

	Kruskal Wallis/Anova test		
	p-value	Times	Significance
>	0,792	TO	NS
DEEP SKIN HYDRATION	1,000	T1h	NS
products comparison	1,000	T6h	NS
time by time	0,427	T24h	NS
	0,896	T48h	NS

Legend: S = statistically significative

NS = statistically not significative

na = not applicable (Friedman/Anova test not significant)

# STATISTICAL ANALYSIS - SUMMARY TABLE INSTRUMENTAL EVALUATION (5)

EPICUTANEOUS pH	Friedman/Anova test	Dur	nett test
comparison vs T0	p-value	Times	Significance
		T0-T1h	NS
Lipogel	0.0100 S	T0-T6h	NS
soluzione P 1%	0.0100 5	T0-T24h	NS
		T0-T48h	NS
	0.000 S	T0-T1h	*p<0,05
ldrogel		T0-T6h	NS
soluzione B		T0-T24h	NS
		T0-T48h	NS
		T0-T1h	NS
Lipogel	0.000 S	T0-T6h	NS
soluzione controllo 1%	0.000 5	T0-T24h	*p<0,05
		T0-T48h	*p<0,05
***************************************		T0-T1h	*p<0,05
Idrogel soluzione controllo	0.000 S	T0-T6h	NS
	0.000 5	T0-T24h	NS
		T0-T48h	NS

	Kruskal Wallis/Anova test		Tukey test	
	p-value	Times	Products comparison	Significance
:	0,824 NS	T0	-	na
	0,000 S <b>T1h</b> -	Lipogel soluzione P 1% vs Idrogel soluzione controllo	S	
EPICUTANEOUS pH 0,000 S products comparison time by time			Idrogel soluzione B vs Lipogel soluzione P 1%	S
			ldrogel soluzione B vs Lipogel soluzione controllo 1%	S
			Lipogel soluzione controllo 1% vs. Idrogel soluzione controllo	S
	0,263 NS	T6h	_	na
	1,000 NS	T24h	-	na
	0,305 NS	T48h	_	na

Legend: S = statistically significative

NS = statistically not significative

na = not applicable (Kruskal Wallis/Anova test not significant)

# STATISTICAL ANALYSIS - SUMMARY TABLE INSTRUMENTAL EVALUATION (6)

TEWL	Friedman test	Dunnett test		
comparison vs T0	p-value	Times	Significance	
		T0-T1h	*p<0,05	
Lipogel	0.000 S	T0-T6h	NS	
soluzione P 1%	0.000 5	T0-T24h	NS	
		T0-T48h	*p<0,05	
		T0-T1h	*p<0,05	
ldrogel	0.001 S	T0-T6h	NS	
soluzione B		T0-T24h	NS	
		T0-T48h	*p<0,05	
		T0-T1h	*p<0,05	
Lipogel	0.000 S	T0-T6h	NS	
soluzione controllo 1%	0.000 3	T0-T24h	*p<0,05	
		T0-T48h	*p<0,05	
	0.000 S	T0-T1h	*p<0,05	
Idrogel		T0-T6h	NS	
soluzione controllo		T0-T24h	*p<0,05	
		T0-T48h	*p<0,05	

	Kruskal <sup>v</sup>	Wallis/Anova te	est
	p-value	Times	Significance
	0,808	ТО	NS
TEWL	1,000	T1h	NS
products comparison	0,465	T6h	NS
time by time	0,757	T24h	NS
	1,000	T48h	NS

Legend: S = statistically significative

### STATISTICAL ANALYSIS - SUMMARY TABLE

## **INSTRUMENTAL EVALUATION (7)**

	SURFACE MICRORELIEF	Wilcoxon/Student t test		t
	(PROFILOMETRY) comparison vs T0	p-value	Times	Significance
	Lipogel soluzione P 1%	0,1247	T0-T48h	NS
Sa parameter	ldrogel soluzione B	0,0054	T0-T48h	**p<0,01
Sa para	Lipogel soluzione controllo 1%	0,1369	T0-T48h	NS
	Idrogel soluzione controllo	0,8514	T0-T48h	NS

	Kruskal Wallis/Anova test				
	p.	-value	Times	Significance	
SURFACE MICRORELIEF (PROFILOMETRY)	Sa	1,000	ТО	NS	
products comparison time by time	ъa	1,000	T48h	NS	

Legend: S = statistically significative

# **PROCEDURE**

DermIng S.r.I., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com

#### STUDY PROCEDURE

## SHORT TERM EVALUATION OF THE SOOTHING AND RE-EPITHELIZING ACTIVITY OF IDRO/LIPO-GEL FORMULATIONS VS REFERENCE PRODUCTS

Test code: E0715

#### Sponsor:

Fondazione Samiarc Via Lanzone, 7 20123 Milano (MI) Italy

#### Study conducted by:

DermIng S.r.l. Single Member Company Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 20900 Monza (MB) Italy

#### **Investigators:**

Responsible of the Study: Dr. Andrea Pensotti

Fondazione Samiarc

Main Investigator: Dr. Adele Sparavigna

Clinical Research Director DermIng S.r.l.

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

#### 1. AIM OF THE STUDY

Aim of the study is to evaluate the soothing and re-epithelizing activity of a single application of two idro/lipo-gel formulations on experimentally induced erythema by repeated tape stripping on the skin forearm (volar surface) of 20 healthy volunteers.

#### 2. MATERIALS

- Densitometer X-RITE 404 (U.S.A)
- Chroma meter CR 200 Minolta (Japan)
- Tewameter® TM300 (MPA 5 Courage-Khazaka, Germany).
- Corneometer CM825 (Courage Khazaka, Köln, Germany)
- MoistureMeterD (Delfin Technologies, Kuopio Finland)
- pH meter HI5221 and electrode with flat tip HI11413B (Hanna® Instruments USA)
- Primos compact portable (GFMesstechnik)
- Clear tape 15.mm (Scotch® 3M Italy).

#### 3. STUDY DESIGN

Double blind trial conducted by one centre, under the supervision of a dermatologist.

Study products activity will be evaluated versus the reference products.

Five visits will be performed during the study: a basal visit after erythema induction (T0), three intermediate visits 1, 6 and 24 hours after products application (T1h, T6h and T24h) and a final visit after 48 hours (T48h).

#### 4. RECRUITMENT OF THE VOLUNTEERS

#### 4.1. Recruitment, selection and admission

The recruitment, selection and admission procedure of volunteers who accepted, on the basis of free, clear and expressed consent to take part in this study, has been elaborated in order to guarantee clear and precise information about the purposes and the consequences of the research.

This procedure involves a meeting with the investigator who will explain to each volunteer the purposes of the research, the expected duration of the test, the frequency of the examinations, the description of the procedures to be followed, any foreseeable risks to the subject, expected benefits of the test. The volunteer will be able to ask questions and to receive clear and exhaustive answers. Afterwards, each volunteer must sign a standard consent form that includes the following elements:

- I) an explanation of the purposes of the research, the expected duration of the test and frequency of the examinations, a brief description of the procedures to be followed;
- II) information about any foreseeable risks to the subject;
- III) a description of the expected benefits of the test;
- IV) a statement describing the confidentiality of records;
- V) name and telephone number of the dermatologist to be contacted for additional information about the research and in case of a research-related injury to the subject;
- VI) a statement that the participation in the study is completely voluntary and free of charge;
- VII) a statement that the treatment of obtained data is made according to Italian Law n°196 of 30.07.2003;
- VIII) a statement that participation in the study can be interrupted by the volunteers without any consequence to them.

DermIng S.r.l.,

Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

The definitive admission of the volunteers is determined by the investigator on the basis of their correspondence to inclusion and exclusion criteria, fixed by protocol, as well as to the interdiction and restriction criteria cited in the protocol.

#### 4.2. Characteristics of the population to be included

The study will be conducted on 20 healthy volunteers of both genders, aged more than 18 years old. The subjects will be precisely informed about the study and will sign a consent form. Any cosmetic treatment and/or exposure to the sun or to UV light, on the test area, will not be permitted during the previous 2 weeks and during all the study period.

#### 4.3. Source

Volunteers are selected from the general volunteer panel belonging to the centre.

#### 4.4. Recruitment of the volunteers

#### 4.4.1. Inclusion criteria

- Adult volunteers of both sexes, aged more than 18 years old
- TEWL value on tested skin areas immedialely after tape stripping ≥15g/m²-h
- Volunteers in a good general state of health in the Investigator opinion
- Volunteers not taking drugs or undergoing surgical procedure
- Volunteers who are giving a written informed consent.

#### 4.4.2. Exclusion criteria

#### 4.4.2.1 Dependent on the volunteers' characteristics

- Pregnancy (only for female subjects)
- lactation (only for female subjects)
- TEWL value on tested skin areas immedialely after tape stripping <15g/m<sup>2</sup>-h
- change in the normal habits in the last month
- participation in a similar study during the previous month
- known allergy to one or several ingredients of the products on trial
- insufficient adhesion to the study protocol.

#### 4.4.2.2. Dependent on a clinical condition

- Dermatological disease
- clinical and significant skin condition on the test area (e.g. lesions, scars, malformations)
- diabetes
- endocrine disease
- hepatic, renal or cardiac disorder
- cancer.

#### 4.4.2.3. Dependent on a pharmacological treatment

- Topical drugs or surgical procedure on the test areas during the previous 3 months
- systemic corticosteroids
- aspirin or non-steroid anti-inflammatory drugs (FANS)
- diuretic drugs
- antibiotics and chemotherapics
- pshycotropic drugs
- retinoids
- psoralens
- cardiologic and vascular drugs.

#### DermIng S.r.l.,

Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

The use of other drugs, not mentioned above, can be authorised by the Investigator. The trade name, the dosage, the start and stop date of the therapy will be reported on the Case Record Form (CRF).

#### 4.5. Restrictions

During the period of treatment normal cleansing habits have to be maintained, sun and UV light exposure, other cosmetic and aesthetic treatments have to be avoided on the tested area.

#### 5. CASE RECORD FORM

The investigator will use an electronic CRF (eCRF) specially engineered "ad hoc" for the study by a trained and specialized DermIng technician. In the eCRF all information about subjects (personal data, subject's history, inclusion/exclusion criteria, clinical evaluations, instrumental data etc.) will be recorded directly on a tablet (interactive form).

The tabulation of the collected data is direct and totally automatic (not manual), assuring an higher level of quality and security.

Every step of the eCRF creation and filling processes are performed in accordance to DermIng internal quality procedure assuring the validation of data and the prevention of data loss.

#### 6. SAMPLE ACCEPTANCE, IDENTIFICATION AND APPLICATION

#### 6.1. Samples record

The products to be tested are recorded, with a reference number, in the Human Studies Record Book together with additional information such as the arrival date, the test requested, Sponsor's name, the product code, the order number and any other information reported on the container.

#### 6.2. Samples storage

Samples to be tested are supplied by the customer and are kept in a dark site at room temperature. During the twelve months following the issue date of the report, a counter-sample will be kept in the same conditions as those described above.

Samples management will be conducted by DermIng according to modalities reported on company operating procedures (SOPs).

#### 6.3. Site of application

Site of application are the forearms (volar surface).

#### 6.4. Quantity of products applied

Test products are applied at the rate of 2mg/cm<sup>2</sup> for each study area (14 cm<sup>2</sup>).

#### 6.5. Application and absorption of the study products

Test products will be applied by the investigator with gloved fingers and light massage, on adjacent cutaneous areas, turning in accordance with a randomization list and left absorbing on the skin.

#### 7. TREATMENT EVALUATION

#### 7.1. Preliminary examination

Volunteers are examined by the Dermatologist who ensures that the skin areas to treat are free from dermatitis and that each volunteer has understood the test, the consent form being completed and signed.

#### DermIng S.r.l.,

Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

Clinical and instrumental measurements will be performed on each skin tested areas (study and reference products treated areas), in basal conditions (T0 - immediately after stripping execution) and 1 (T1h), 6 (T6h), 24 (T24h) and 48 (T48h) hours from products application.

#### 7.2. Skin erythema induction

Skin erythema will be induced on the subjects' forearms by repeated tape stripping. Tape stripping is a technique used in dermatological research to selectively and exhaustively remove the skin's stratum corneum. In particular the skin of the forearms will be stripped with repeated applications of clear tape 15.mm (Scotch® 3M – Italy); for each skin tested area 40 tape stripping performed by the same specialised technician are required to achieve the barrier disruption.

#### 7.3. Soothing efficacy evaluation

#### 7.3.1. Clinical evaluation of skin erythema

Skin erythema is scored and recorded according to the grades reported in the following table:

- 0 no erythema
- 0.5 very slight erythema (barely perceptible)
- 1 well-defined erythema
- 1.5 moderate to severe erythema
- 2 severe erythema (beet redness) to slight eschar formation (injuries in depth).

#### 7.3.2. Instrumental evaluation of skin erythema

#### 7.3.2.1. Optical densitometry

An optical densitometer (X-RITE 404) allows to quantify, on a logarithmic scale, the total reflected optical density (visual=V) and the values of primary subtractive colours of reflected light: cyan(=C), magenta(=M) and yellow(=Y). The erythema index is calculated as follows:

#### E.I.=logRmagenta-logRcyan

#### 7.3.2.2. Optical colorimetry

Chroma Meter CR-200® is a tri-stimulus colorimeter equipped with three special filters which allows to obtain R,G,B values in accordance with CIE (Commission Internationale de l'Eclarage), the main international organisation concerned with colour and colour measurement.

CIE  $L^*a^*b^*$  system (CIELAB) is the most complete colour-space specified by the CIE (1976). It describes all the colours visible to the human eye; the three coordinates of  $L^*a^*b^*$  represent the lightness of the colour ( $L^*=0$  yields black and  $L^*=100$  indicates diffuse white; specular white may be higher), its position between red/magenta and green ( $a^*$ , negative values indicate green while positive values indicate magenta) and its position between yellow and blue ( $b^*$ , negative values indicate blue and positive values indicate yellow).

#### 7.4. Re-epithelizing efficacy evaluation

#### 7.4.1. Transepidermal water loss (TEWL)

In normal intact skin, the stratum corneum is a very effective barrier so the water loss rate, which is expressed in terms of the amount of water evaporated per unit area of skin (TEWL) in absence of sweating, is low. The measurement of TEWL allows to objectively monitor skin responses to cosmetic treatments. Decreased water loss rates accompany treatments which occlude skin surface (e.g. lipid coating). Occlusion of the skin is not cosmetically accepted. A shift from high water loss rates in subjects with altered skin barrier function to normal rates could mean skin lipids replacement and restored barrier function. On the contrary a shift from low-normal rates of TEWL

DermIng S.r.l.,

Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

to high levels is due to barrier disruption. In case of moisturising products, humectant ingredients may act by encouraging the normal circulation of water from low layers of the epidermis and allow this water to evaporate from the surface.

#### 7.4.2. Electrical capacitance of skin (superficial hydration)

Superficial hydration is measured by the instrument Corneometer CM825 (Courage – Khazaka, Köln, Germany): a square sensor (49mm²) frontally covered by a special glass, mounted on a spring cursor able to measure electrical capacity. Leaning the sensor on the skin surface, with a constant pressure thanks to the spring cursor it is possible to perform measures. The sensor acts as a capacitor. When a voltage is applied to this capacitor, the quantity of electric charge stored will be dependent on the dielectric properties of the material in contact with the probe. Water has an unusually high dielectric constant and so its presence in the skin is readily detectable by this method. So the measure of the skin capacitance properties is an indirect expression of its hydration level.

To reduce the variability of measurement methods, for each volunteer, three measures on the same skin area will be executed: the adjusted mean will be considered as the real measure value.

### 7.4.3. Tissue dielectric constant of deep skin layers (deep hydration)

The MoistureMeterD measures non-invasively the dielectric constant of the skin and subcutaneous fat. The dielectric constant is a dimensionless physical quantity and it is directly proportional to the water content in the measured tissue. The MoistureMeterD generates a high frequency, low power electromagnetic (EM) wave which the tissue is exposed to. The reflected EM wave is registered and the obtained value is a dielectric constant, which is proportional to the water content of the measured tissue; the measured value increases when water content increases.

The dielectric constant of water molecules depends on the used radiofrequency. Free and bound water behave electrically differently with different frequencies. At around 300 MHz, the electrical properties of free and bound water are quite identical, thus the MoistureMeterD measures changes in the total water content of the tissue.

The measurement depth can be determined by using differently sized probes (the deeper the measurement need the larger the probe); for this study a 1.5 mm depth probe was used.

#### 7.4.4. Epicutaneous pH

Surface cutaneous pH represents a useful signal of epidermis state health.

The hydrogenionic concentration on cutaneous surface is measured by an instrument composed by a flat combined bottom cylindrical sensor. Measurements are performed by leaning the electrode flat tip on skin surface; after few seconds on the display appears the pH value.

#### 7.4.5. Microrelief surface evaluation (profilometry)

The microrelief surface evaluation is determined with the "surface roughness evaluation" function in the Primos 3d portable software. Through the use of this function, the software evaluates the whole area of the acquired image. Once evaluation is complete, all the surface parameters are saved in an external file, which will then be imported into an excel table.

The primary profilometric parameter analyzed in this study will be Sa (average roughness), that represents an overall measure of the surface texture.

#### 7.5. Standard conditions for the treatment evaluations

Before the clinical and instrumental measurements the volunteer will be acclimatised under relax conditions for at least 15 min. During the 3 hours before the test, the volunteer must not smoke,

DermIng S.r.l.,

Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

drink coffee or alcohol and must not use on the skin test area any product. The instrumental measurements are performed under standard environmental conditions (Temperature=22+\-2°C; Relative Humidity<60%).

#### 8. SCHEDULE OF STUDY PROCEDURE

#### 8.1. Baseline visit (T0)

The visit includes:

- filling the CRF (personal data)
- visual examination of the tested side
- identification and assignment of 4 skin areas under test on the forearms (according to a randomisation list)
- skin erythema induction (repeated tape stripping)
- clinical and instrumental evaluation (clinical and instrumental assessment of skin erythema and pH, TEWL, superficial and deep hydration measurement).
- profilometry skin image acquisition
- study products application.

#### 8.2. Intermediate visits (1, 6 and 24 hours after products application)

These visits includes:

- clinical and instrumental evaluation (clinical and instrumental assessment of skin erythema and pH, TEWL, superficial and deep hydration measurement).

#### 8.3. Final visit (48 hours after products application)

These visit includes:

- clinical and instrumental evaluation (clinical and instrumental assessment of skin erythema and pH, TEWL, superficial and deep hydration measurement)
- profilometry skin image acquisition.

#### 9. PREMATURE END OF THE STUDY/ END OF THE STUDY

#### 9.1. Withdrawal criteria

Any person who in the course of the trial:

- decides to withdraw the consent for any reason
- does not present to the study visits
- does not comply with the treatment
- develops any of the conditions specified in the original exclusion criteria
- contracts a serious illness that does not allow the study continuation.

#### 9.2. Procedure

All breaks in a volunteer's participation in the trial have to be recorded in the study termination form the reasons for discontinuation being mentioned. In case of volunteers did not perform the expected visit, the Investigator has to try to understand the reason of the absence.

#### 9.3. Restrictions

The volunteers who stop the trial, cannot be enrolled again or be replaced by other volunteers with the same randomization number.

DermIng S.r.l.,

Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

#### 10. STATISTICAL ANALYSIS PLAN

#### 10.1. Main criteria

The statistical evaluations of clinical and instrumental data (adjusted means and standard deviation) and relative graphs will be performed at the times required by the protocol. The values will be rounded off to the decimal in accordance to our internal procedures.

#### 10.2. Population description

This sample includes all subjects that completed the study according to the protocol.

#### 10.3. Clinical data

The statistical analysis of clinical data is carried out with not parametric test.

#### 10.4. Instrumental data

The analysis of all numeric parameters (arithmetic mean, standard deviation) are carried out by non-parametric test (Friedman/Kruskal Wallis test) when the normality hypothesis is rejected by the Shapiro-Wilk normality test (threshold at 5%) and by parametric test (one way ANOVA/ANOVA for repeated measures), when the normality hypothesis is confirmed.

#### 10.5. Statistical plan

The activity of the tested products at T1h, T6h, T24h and T48h will be expressed in absolute values versus baseline (T0) and in comparison to each other.

#### 11. QUALITY CONTROL AND ASSURANCE

This trial is carried out by DermIng in accordance with the methods described in the company standard operating procedures (SOP). The information and data on the trial are generated, recorded, documented and processed in accordance with the methods described in the following procedure, based on ICH GCP 1996.

#### 12. ETHIC

#### 12.1. Commitment attestation of insurance

The test starts only after the evaluation of the documentation provided by the Sponsor (with products identification, date and Sponsor signature).

This documentation contains: the declaration that the products are submitted to the E.C.C. legislation, the qualitative composition of the products with the declaration that any component presents a serious toxicological effects at the established concentration, all available data about toxicological and tolerability pre-clinical prove, the normal conditions products use, an attestation of insurance that ensures the risks for volunteers using the articles.

#### 12.2. Consent form for the volunteer

Each volunteer is precisely informed about the study, a consent form being completed and signed (Appendix 1). At the end of the study the investigator will declare to have informed all the volunteers participating it, signing and dating the relative form (Appendix 2).

DermIng S.r.l.,

Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

#### 13. BIBLIOGRAPHY

Altemus M. et al.

Stress-induced changes in skin barrier function in healthy women.

J. Invest. Dermatol., 117 (2): 309-317; August 2001

#### Blank I.H.

Measurement of pH of the skin surface. II. pH of the exposed surfaces of adults with no apparent skin lesions.

J. Invest. Dermatol., 2:75-79; 1989

Corcuff P, Chatenay F, Leveque JL

A fully automated system to study skin surface patterns.

Int. J. Cosmet. Sci. 6:167-176; 1984

Elsner P., Berardesca E., Maibach H.

Bioengineering of the skin: Water and the stratum corneum.

CRC Press, Boca Raton, 1994

Fernay, Voltaire

"World Medical Association Declaration of Helsinki"

The World Medical Association, Hong-Kong (1989)

Fuga GC, Spina C, Cavallotti C, Di Palma A, Lombardi G, Marmo W

Computerized reflected optical densitometry. A research on the colour of the skin.

J. of Applied Cosmetology, 8:91-110; 1990

Fullerton A. at al.

Guidelines for measurement of skin colour and erythema.

A report from the standardization Group of the European Society of Contact

Contact Dermatitis. Jul;35(1):1-10; 1996

Gao Y. et al.

Acute skin barrier disruption with repeated tape stripping: an in vivo model for damage skin barrier.

Skin Res. Technol.: 19(2):162-168; May 2013

Hashimoto K

New methods for surface ultrastructure: comparative studies or scanning electron microscopy,

transmission electron microscopy and replica method.

Int J Dermatol 131: 357-381; 1974

ICH Harmonised Tripartite Guideline - Guideline for Good Clinical Practice

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: May 1996.

Mayrovitz H.N., Carson S. and Luis M.

Male-female differences in forearm skin tissue dielectric constant

Clin. Physiol. Funct. Imaging, Sep;30(5):328-32; 2010.

DermIng S.r.l.,

Clinical Research and Bioengineering Institute

Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

Test code

E0715

Mayrovitz H.N.

Local tissue water assessed by measuring forearm skin dielectric constant: dependence on measurement depth, age and body mass index

Skin Research and Technology 16: 16–22; 2010.

Pinnagoda J, Tupker RA, Agner T, Serup J

Guidelines for transepidermal water loss (TEWL) measurements. A report from the Standardisation Group of the European Society of Contact Dermatitis

Contact Dermatitis, 22: 164-178; 1990

Qi Q. et al.

A correlational study of areal surface texture parameters on some typical machined surfaces.

13th CIRP conference on Computer Aided Tolerancing

Procedia CIRP, 27:149-154; 2015

Rosén B.-G. et al.

On in-vivo skin topography metrology and replication techniques

J. Physics: Conference series, 13: 325-329; 2005

Sachs L.

Applied statistics: a handbook of techniques

Heidelberg: Springer, 536-539; 1981

Serup J, Agner T

Colorimetric quantification of erythema - a comparison of two colorimeters (Lange Micro Color and Minolta Chroma Meter CR-200) with a clinical scoring scheme and laser-Doppler flowmetry. Clin. and Exper. Dermatology, July 1990; vol. 15, Issue 4, pages 267-272.

Tagami H. et al.

Evaluation of skin surface hydration in vivo by electrical measurements

J. Invest. Dermatol., 75: 500-507, 1980

Takiwaki H.

Measurement of skin color: practical application and theoretical considerations.

The J. of Med. Investigation vol.44:121-126; 1998

Tsai J.-C. et al.

Properties of adhesive tapes used for stratum corneum stripping.

Int. J. of Pharmaceutics, 72: 227-231; 1991

#### 14. APPENDICES

- 1) Information for the volunteers and informed consent form
- 2) Certificate of subjects information

DermIng S.r.l.,

Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY

Tel.: 039/329666 - www.derming.com

# **APPENDICES**

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com



#### MODULO DI CONSENSO LIBERO E CONSAPEVOLE

#### INFORMAZIONI

Sono stato invitato/a a partecipare ad uno studio clinico che valuti l'attività lenitiva e ristrutturante di 2 prodotti cosmetici ad uso topico, formulati e prodotti in conformità alla normativa vigente, verso 2 prodotti di riferimento.

In particolare su 4 piccole aree cutanee, 2 per ogni avambraccio (superficie volare), verrà determinato un leggero arrossamento mediante "stripping corneo ripetuto"; si tratta di un semplice strappo di cellule morte di superficie mediante l'utilizzo di scotch, che verrà ripetuto più volte a livello della stessa sede cutanea. Quindi lo sperimentatore applicherà sulle 4 aree una piccola quantità dei prodotti in studio.

Le valutazioni cliniche (valutazione visiva del grado di arrossamento) e le misurazioni sperimentali (indice di eritema, idratazione superficiale e profonda, pH, perdita d'acqua transepidermica, ripresa del microrilievo di superficie), del tutto innocue ed indolori, verranno eseguite dopo 1 ora, 6, 24 e 48 ore dall'applicazione dei prodotti. Nelle 3 ore precedenti le suddette valutazioni no dovrò fumare, bere caffè o alcolici, sottoporre le sedi cutanee oggetto del test ad alcun trattamento.

Per poter partecipare allo studio non devo presentare alterazioni cutanee nell'area destinata al saggio quali ferite, cicatrici, malformazioni ecc. Per questo motivo il dermatologo valuterà lo stato di salute della mia pelle prima di decidere la mia inclusione nella sperimentazione.

#### **CONSENSO**

Accetto di partecipare alla prova sopraindicata, ossia:

"Valutazione dell'efficacia lenitiva e ristrutturante di due prodotti cosmetici destinati ad uso topico vs prodotti di riferimento".

Dichiaro di essere stato/a informato/a degli obiettivi, delle condizioni, della durata dello studio, della possibile comparsa di fenomeni di intolleranza al trattamento (ad es. irritazione, allergia ecc.) / art. 13 D.LGS 30 GIUGNO 2003 N°196).

Nulla mi sarà addebitato per la partecipazione al test (la prova è interamente a carico di DermIng) e non riceverò alcun compenso. Anche in caso di accettazione rimango libero/a di interrompere la prova in qualsiasi momento, senza fornire spiegazioni: mi impegno unicamente a comunicare la mia decisione al medico. Dichiaro di aver ricevuto risposte esaurienti relative alle mie domande sullo studio in oggetto. Autorizzo espressamente DermIng ad elaborare sul computer le informazioni che mi riguardano. Avrò la possibilità di avere accesso a queste informazioni, di correggerle o di annullarle (se lo ritengo necessario) presso il Centro DermIng, Viale Cesare Battisti, 38 a Monza (MB) (art. 7 D.LGS 30 GIUGNO 2003 N°196). Accetto inoltre che i risultati di queste ricerche siano comunicati (rispettando l'anonimato) da DermIng alla Società Committente. I dati ottenuti saranno resi anonimi ed utilizzati esclusivamente per scopi scientifici e statistici.

(2 copie di cui una in mio possesso)

INome:	
Ci+tà:	
Monza, lì	
Adele Sparavigna	
Rev. 06 del 01.02.12	Pagina 1 di 2
nical Research and Bioengineering Institute	
Battisti, 38 - 20900 Monza (MB) - Italy	
39/329666 - www.derming.com	
Test code	
E0715	
	Città: Monza, lì  Adele Sparavigna  Rev. 06 del 01.02.12  nical Research and Bioengineering Institute Battisti, 38 - 20900 Monza (MB) - Italy 19/329666 - www.derming.com Test code



### MODULO DI ARRUOLAMENTO DermIng, Istituto di Ricerche Cliniche e Bioingegneria

	Per	poter	essere ammessi	allo studio	in corso il	l soggetto non	deve presentare	nessuna delle s	seguenti	condizioni
--	-----	-------	----------------	-------------	-------------	----------------	-----------------	-----------------	----------	------------

Dermatiti; Psoriasi; Eczemi;

Dermatite seborroica;

<ul> <li>Dermatite atopica;</li> </ul>		
- Orticaria;		
- Vitiligine;		
- Allergie a prodotti cosmetici;		
- Presenza di alterazioni cutanee nell'area de	stinata all'esecuzione del saggio;	
- Diabete;		
- Disendocrinie;		
- Malattie autoimmunitarie;		
- Alterazioni ormonali;		
<ul> <li>Malattia epatica evolutiva;</li> </ul>		
- Insufficienza renale;		
- Insufficienza cardiaca;		
<ul> <li>Malattie neoplastiche evolutive;</li> </ul>		
- Tumori della pelle;		
- Gravidanza;		
- Allattamento.		
meno di tre mesi antecedenti lo studio;  - Diuretici;  - Cicli di chemioterapia.	enti di tipo medico e/o chirurgico a livello delle sedi di c	applicazione eseguite da
NOME:		
NOME:  COGNOME:  LUOGO DI NASCITA:  FIRMA:	DATA DI NASCITA:	
COGNOME:	DATA DI NASCITA:	
COGNOME: LUOGO DI NASCITA: FIRMA:	DATA DI NASCITA:	  Pagina 2 di 2
COGNOME:  LUOGO DI NASCITA:  FIRMA:  Mod09_ Moduli registrazioni volontario prova  DermIng S.r.l., G  Viale Cesar	DATA DI NASCITA:  DATA:  Rev. 06 del 01.02.12  Clinical Research and Bioengineering Institute re Battisti, 38 - 20900 Monza (MB) - Italy re 3039/329666 - www.derming.com	
COGNOME:  LUOGO DI NASCITA:  FIRMA:  Mod09_ Moduli registrazioni volontario prova  DermIng S.r.l., G  Viale Cesar	DATA DI NASCITA:  DATA:  Rev. 06 del 01.02.12  Clinical Research and Bioengineering Institute re Battisti, 38 - 20900 Monza (MB) - Italy	

#### CERTIFICATE OF SUBJECTS INFORMATION

Regarding the study:

## SHORT TERM EVALUATION OF THE SOOTHING AND RE-EPITHELIZING ACTIVITY OF IDRO/LIPO-GEL FORMULATIONS VS REFERENCE PRODUCTS

Test code: E0715 Prot: 2647, 2648, 2649, 2650

I, Dott. Adele Sparavigna, certify that all subjects were informed about the study protocol modalities and their relatives rights, and that I have obtained their informed consent form.

Date: 05/29/2015

Signature

DermIng S.r.l., Clinical Research and Bioengineering Institute Viale Cesare Battisti, 38 - 20900 Monza (MB) - ITALY Tel.: 039/329666 - www.derming.com